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ABSTRACT 
A strategy for the total chemical synthesis and purification of proteins has been 
investigated and applied to the 85 residue methylated DNA binding domain (MBD) 
from the chromosomal protein MeCP2, the 66 residue Restriction Alleviation (Ral) 
protein from bacteriophage a, and the 76 residue ß- chemokine Monocyte 
Chemotactic protein (MCP -1). The hydrophobicity of the Na protecting group 
tetrabenzo[ a, c ,g,i]fluorenyl- 17- methoxyc)bonyl (Tbfmoc) has been exploited to 
simplify the rapid purification of the 85 amino acid MBD protein by Hplc. Initial 
structural studies on the synthetic protein are also reported. In addition a comparative 
study of semi -permanent, temporary and enzyme cleavable thiol protection has 
resulted in the extention of this Tbfmoc methodology to the synthesis of cysteine 
containing proteins such as Ral and MCP -1. 
A general route to C- terminal a- hydroxyglycine extended peptides via Fmoc /t -Bu 
based solid phase peptide synthesis is also described. Such peptides are the 
biosynthetic precursors of peptide amides in which the C- terminal carboxamide 
functionality is required for biological activity in a number of important hormones. 
ABBREVIATIONS 
A adenosine 
Aba aminobutyric acid 
Acm acetamidomethyl 
AcOH acetic acid 
a -AE a- amidating enzyme 
Boc tert- butyloxycarbonyl 





CD circular dichroism 
CpG deoxycytidyldeoxyguanosine dinucleotide 
Da dalton 
DCCI N,N'- dicyclohexylcarbodiimide 
DIC N,N'- diisopropylcarbodiimide 
DIEA N,N- diisopropylethylamine 
DKP diketopiperazine 
DMF N,N- dimethylformamide 
DNA deoxyribonucleic acid 
DTNB 5,5'- dithiobis(2- nitrobenzoic acid) 
DTT dithiothreitol 
EDT ethane -1,2- dithiol 
EDTA ethylenediaminetetraacetic acid 
FdC 5- fluoro -T- deoxycytidine 
Fmoc 9- fluorenylmethoxycarbonyl 
G guanosine 
Gdm.HC1 guanidinium hydrochloride 
HOBt 1 -hydroxybenzotriazole 
HPLC high performance liquid chromatography 
IL interleukin 
MBH 4,4'- dimethoxybenzhydryl 
MBD methylated DNA binding domain 
MALDITOF matrix assisted laser desorption ionisation time of flight 
MCP -1 monocyte chemotactic peptide 
MEM 2- methoxyethoxymethyl 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser enhancement 
NOESY nuclear Overhauser correlation spectroscopy 
aOHG a- hydroxyglycine 
PAL peptidylamidoglycolate lyase 
Pfp pentafluorophenyl 
PGC porous graphitised carbon 
PHM peptidyl- a- hydroxyglycine monooxygenase 
pI isoelectic point 
Pmc 2, 2, 5, 7, 8- pentamethylchroman -6- sulphonyl 
PSA preformed symmetrical anhydride 
PyBOP benzotriazole- l- yl -oxy -tris- pyrrolidino -phosphonium 
hexafluorophosphate 
RP -HPLC reverse phase HPLC 
Ral restriction alleviation 
Rt retention time 
SAM S- adenosyl -L- methionine 
SC salmon calcitonin 
SDS -PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SKB SmithKline Beecham 
SPPS solid phase peptide synthesis 
T thymidine 
Tacm trimethylacetamidomethyl 
Tbfmoc tetrabenzo[ a, c, g,i]fluorenyl -17- methoxycarbonyl 
TFA trifluoroacetic acid 
TFE 2,2,2 -trifluoroethanol 
THP tetrahydropyranyl 
t.l.c. thin layer chromatography 
TMSBr trimethylsilyl bromide 
TRIS tris(hydroxymethyl)aminomethane 
Trt triphenylmethyl 




3 Letter Code 1 Letter Code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamic Acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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CHAPTER ONE : INTRODUCTION 
1.1 Introduction 
The publication in 19631 of the first solid phase synthesis of a polypeptide, heralded 
the start of a technological revolution which has had a major influence on the 
progress of twentieth century chemical and biotechnological research. Prior to Bruce 
Merrifield's beautifully simple idea of covalently immobilising the growing peptide 
chain on an insoluble support, the synthesis of polypeptides in solution was a labour 
intensive and lengthy process requiring the purification and isolation of each 
intermediate compound. A consequence of this protracted synthetic route being that 
the assembly of relatively short peptide sequences required a major research effort 
from even the most experienced and well equipped laboratories. 
The intervening thirty years have seen technological advances in commercially 
available solid phase peptide synthesisers refined to such an extent, that many 
manufacturers claim the fully automated synthesis of peptides is "easy"2 and that an 
operator only has to enter the required sequence, push "START" and walk away. 
Although the reality, as any peptide chemist will readily confirm, is that even a 
seemingly innocuous sequence of amino acids can hide synthetic difficulties which 
serve to remind us that the chemistry of amide bond formation and the associated 
protecting group strategies cannot be taken for granted simply because they are 
carried out under microprocessor control. 
The advent of automated solid phase peptide synthesis (SPPS), was welcomed by 
those working in the fields of medicine and biological science who required peptides 
and were uninterested in how they were produced. To the organic chemistry purist, 
however, the lack of characterisation of intermediates was seen as the major worry. 
1 
This concern has largely been overcome, due to the refinements introduced by 
Merrifield and others, which have resulted in the basic principle being extended to 
other areas such as oligonucleotide synthesis, peptide sequence analysis and related 
technologies. 
1.2 The Merrifield Approach - Boc Strategy 
The basic principles reported in Merrifield's initial publication are outlined in 
Scheme 1. The second synthesis from Merrifield's laboratory3 reported the 
replacement of the initially favoured benzyloxycarbonyl (Z) Na protecting group (1) 




The C- terminal Na protected amino acid residue was attached to the insoluble 
support, formed by crosslinking polystyrene with divinylbenzene and 
chloromethylating, by nucleophilic displacement. The Boc group was then removed 
by treatment with mild acid, followed by neutralisation, to give a free amino group 
to which the second Na protected amino acid was coupled using N,N- 
dicyclohexylcarbodiimide (3). The deprotection, neutralisation and coupling steps 
were then repeated with other Boc protected amino acids to build up, in a stepwise 
fashion, the desired peptide sequence. During assembly all side chain functional 
groups were protected with semi- permanent protecting groups which are stable to the 
mild acid conditions required to remove the temporary Na Boc protection and after 
2 
each step the insoluble polymer bound peptide was thoroughly washed to remove 
excess reagents and reaction byproducts. Finally, the peptide was released from the 
resin with simultaneous removal of all side chain protecting groups by treatment 
with anhydrous hydrogen fluoride. 
C1CH2 
BocNHCHRI CO2 - CH2 
CF3CO2 NH3+CHRiCO2-CH2 
BocNHCHR2CO2NHCHRiCO2- CH2 









Scheme 1. Conditions i, attachment of first amino acid as Cs salt by nucleophilic 
displacement ; ii, Na deprotection with mild acid ; iii, neutralisation followed by 
DCCI mediated coupling of Na protected amino acid ; iv, repetition of ii -iii as 
appropriate ; v, cleavage of peptide from resin with strong acid . 
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Throughout the synthetic operations the growing immobilised peptide -polymer 
conjugate was retained by a glass sinter which minimised mechanical losses and 
allowed for easy removal of reagents by filtration. The major benefits of this 
approach were that it allowed the use of large excesses of reagents in order to force 
reactions to completion and consequently coupling times could be reduced, thus 
allowing the relatively rapid synthesis of peptides which would previously have 
taken several weeks to produce by classical solution phase methods. 
The Merrifield approach, which has changed little over the years since its inception, 
is currently used with great success for the fully automated production of 
polypeptides and has been the subject of many excellent reviews4a,b. 
1.3 Fmoc Solid Phase Peptide Synthesis 
The development of an alternative to Boc synthesis arose out of the incomplete 
orthogonality between the temporary and semi- permanent protecting groups used in 
Boc based chemistry. This resulted in significant losses of peptide from the resin by 
cleavage of the peptide -resin ester linkage during Boc removal with mild acid. The 
required use of the highly dangerous anhydrous hydrogen fluoride to cleave the final 
product from the resin when using Boc based chemistry also required specialised 
laboratory apparatus, and resulted in Boc based methods being unattractive to many 
laboratories. In addition the use of strong acid in the final step may have deleterious 
effects on the peptide product. 
This situation changed with the introduction of the base labile Na protecting group 
9- fluorenylmethoxycarbonyl (Fmoc)5 (4) and its incorporation into automated solid 
phase peptide synthesis6'7'8. The general strategy for Fmoc solid phase peptide 
synthesis (SPPS) is outlined in Scheme 2. 
4 
O - NHCHRNCO NHCHRCO2- FLINKER- POLYSTYRENE] 
ii , iv 
HO -E LINKE POLYSTYRENE] 
i 
O 
NHCHRCO -O 4LINKER- POLYSTYRENE] 
jii 
NH2 CHRCO -O -FLINKER- POLYSTYRENE] 
NH2CHRNCO NHCHRCO2H 
Scheme 2. Conditions i, attachment of first amino acid ; ii, Na deprotect with 
piperidine ; iii, coupling of Na protected amino acid ; iv, cleavage of the peptide 
from the solid support with trifluoroacetic acid . 
The solid support used in standard Fmoc SPPS consists of a crosslinked polystyrene 
which is functionalised with an acid sensitive linker to which the first Fmoc Na 
protected amino acid is coupled. Normally the attachment of amino acid to the linker 
5 
is via an ester linkage, which can be formed by reacting the resin bound linker with a 
preactivated amino acid derivative in the presence of a catalytic amount of 4- 
dimethylaminopyridine (DMAP). The Na protecting group is then removed by 
treatment with base (usually piperidine) to give the intermediate carbamate salt, 
which then undergoes decarboxylation to give the free amine. After thorough 
washing of the resin -bound amino acid, the second Fmoc Na protected amino acid is 
coupled. Coupling (Section 1.3.3) can be achieved using either preactivation, such as 
a preformed symmetrical anhydride (5) or active ester (6), although there is growing 
support for the use of in situ activation where several different activators can be used 
directly without the need to preform the activated amino acid derivative before 





This cycle of coupling and deprotection is repeated until the desired sequence has 
been obtained and then the peptide is released from the resin with simultaneous 
removal of side chain protecting groups by treatment with 95% trifluoroacetic acid. 
Each of the above steps, as generally applied to automated Fmoc SPPS, are 
elaborated on in the following chapters. 
6 
1.3.1 The Solid Support 
Early work on finding suitable resins for Boc based SPPS, identified several factors 
that were important in determining the optimum physical and chemical 
characteristics required for the solid support9.These were: 
(a) Functionality which allows attachment of the desired linker and 
subsequent coupling of amino acids. 
(b) Stability to all reaction conditions. 
(c) The resin must swell sufficiently in the solvent used during synthesis, to 
allow rapid diffusion of reagents. 
These characteristics are found in polymers of styrene when 1% crosslinked by m- 
divinylbenzene, with less than 1% crosslinking the resin produced is too fragile and 
with greater than 1% crosslinking the resin does not swell sufficiently10. This resin 
has found widespread use in both Fmoc and Boc batchwise SPPS, where the resin is 
filtered after each synthetic step. The main disadvantage with using a polystyrene 
based resin is the fact that polystyrene is relatively hydrophobic and it has therefore 
been argued11 that a more hydrophilic support should help solvate the growing 
peptide chain and polymer backbone. This in turn should aid diffusion of reagents 
and lead to increased reaction rates and coupling yields for each step, hence 
producing a purer final product. This approach has been successfully applied by 
Atherton and Sheppard to the continuous flow method of Fmoc based SPPS using a 
polyamide resin. In this approach the peptide resin is continually solvated during 
synthesis and this requires a support which can withstand a continuous flow of 
7 
solvent. Polyamide polymers on their own are too fragile to withstand these 
conditions although, by chemically bonding the polyamide to the inorganic support 
kieselguhr, the desired physical characteristics can be achieved and this continuous 
flow polyamide/kieselguhr methodology has been well documented11. 
1.3.2 Resin Linkages 
Final cleavage of peptides synthesised utilising Fmoc SPPS allows the use of resin 
linkers which are much more acid labile than the conventional polystyrene or 







Chang and Meienhofer6 utilised a p- benzyloxybenzylalcohol functionalised 
polystyrene resin (8), previously developed by Wang12, for the first Fmoc solid 
phase synthesis of a peptide acid and this has remained popular due to its acid 
lability (50% trifluoroacetic acid in aprotic solvents). More recently the desire to 
produce fully protected fragments by using extremely mild cleavage conditions, 
which do not affect t -butyl based protecting groups, has led to the development of 
linkers which can be cleaved by very dilute TFA13 (9), acetic acid14 (10) and fluoride 









Besides free acids, linkers have also been used to generate alternative carboxyl 
functionalities for a variety of applications. The Fmoc synthesis of peptides using 
acid cleavable linkers has been reported for production of C- terminal amides16, 
hydrazides16,17 and carboxyl -linked peptide polymers18 to name but a few. 
1.3.3 Coupling Methods - Amide Bond Formation 
The principal reaction in the synthesis of peptides involves the acylation of an amino 
acid by the carboxyl group of a second amino acid to form an amide bond. There 
have been a multitude of amide bond forming methods developed for the synthesis 
of peptides and with very few exceptions these methods are based on the direct 
electophilic acylation mechanism19,2° (Scheme 3). 
RiCO2H 
OI -HX 





Scheme 3. Direct electrophilic acylation mechanism19,20 
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This requires activation of the a- carboxyl group of an Na protected amino acid by 
replacement of the carboxylic acid hydroxyl group with an electronegative 
substituent X, which is susequently displaced by the incoming amine component via 
a tetrahedral intermediate. In general the better the leaving group X -, the more 
powerful the acylating agent RiCOX is and this in turn, is related to the strength of 
the acid HX19. 
1.3.3.1 Racemisation During Activation/Coupling 
One serious concern which must be considered at the activation and coupling stages 
of a synthesis is the danger of racemisation occurring. This side reaction has plagued 
the field of peptide synthesis throughout its history and much time and effort has 
been put into the study of conditions which minimise this undesirable side reaction21. 
The conditions employed during Fmoc SPPS tend to mean that, except for in the 
case of a few special amino acids (e.g. a- arylglycines) and during extremely slow 
couplings, the risk of racemisation occurring by direct enolisation is slight. The main 
cause of racemisation is the cyclisation of activated acyl amino acids (12) under the 
influence of base to give oxazolones (13) and (14) (Scheme 4). 
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(12) 
RN - R R 1- 
0 
(13) O O (15) 
NH2R2 H+ 
R1 1 RN 








Scheme 4. Base catalysed racemisation of acyl amino acids via the oxazolone 
mechanism 
The oxazolones (13) and (14) produced are themselves activated carboxylic acid 
derivatives and reaction with an amine can lead to formation of a peptide. However, 
due to the fact that racemisation via the stabilised anion (15) occurs more rapidly 
than the rate of aminolysis, both possible epimers (16) and (17) are formed. The 
extent of oxazolone mediated racemisation depends very much on the nature of the 
leaving group X' and certain methods of coupling have been shown to produce lower 
levels of racemisation than others. The majority of amide bond forming methods 
have previously been reviewed22,23 and will therefore not be covered in this text . 
Instead the narrower area of those which have been generally applied to Fmoc SPPS 
will be covered here. 
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1.3.3.2 Carbodiimides 
Sheehan and Hess first reported the use of carbodiimides to activate carboxylic acids 
towards aminolysis in 195524, and since that date they have probably been the single 
most important reagent of their type. Dicyclohexylcarbodiimide (DCC) (3) and 
diisopropylcarbodiimide (DIC) (18) are used extensively in solid phase synthesis, 
with the latter being preferred for use on automated synthesisers due to the fact that 
the urea (19), the by- product of the amidation reaction, is more soluble than the 
corresponding N,N- dicyclohexylurea. 
ÌÌ 
> 
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Peptide Active Ester 
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Addition of the carboxy group to the carbodiimide functionality (Scheme 5) gives an 
0-acylisourea (20). This very reactive acylating agent can then either react with a 
free amino group to form the peptide bond, or more usually with oxygen 
nucleophiles to produce an activated ester or symmetrical anhydride. Whilst the 
addition of oxygen nucleophiles generates an acylating reagent of lower reactivity 
with respect to aminolysis than (20), this is beneficial in that it also helps alleviate 
several serious side reactions, such as racemisation (Scheme 4), carboxamide 
12 
dehydration of asparagine /glutamine (Scheme 6) and formation of N- acylureas 
(Scheme 7), which have been found to accompany the generation of reactive species 
such as (20)22. 









Scheme 6. Carbodiimide promoted dehydration of carboxamide side chain to nitrile 
o ArJ 
R ' O } 
H 
Scheme 7. N-acylurea formation 
-pm. 
1.3.3.3 Phosphonium Reagents 
Phosphonium reagents are becoming increasingly popular as direct coupling reagents 
in solid phase peptide synthesis. The di- tetrafluoroborate (21) initially reported by 
13 
Bates et al25 has spawned several related reagents, the most noteable of which are the 








(Me2N)3P -O -N. 
(22) 
(23) 
Attack of carboxylate anion (24) (Scheme 8) at the phosphonium cation (25) forms 
an acyloxyphosphonium species (26), which reacts readily with nucleophiles at the 
acyl carbon. Although several pathways which result in amide bond formation are 
possible, the main route is thought to be via the active ester (27). 
+ 
RCO2- + R'3P-X 
(24) (25) 
O 
I RC` Ó P+R'3 + 
(26) 









Typical coupling reactions utilising phosphonium reagents of this type require no 
need for preactivation. The coupling reagent is simply mixed together with the resin 
bound amino funtional group, the Na protected amino acid and some tertiary base to 
ensure the acid is in its anionic form. This leads to shorter cycle times and can 
dramatically increase the number of amino acids which can be coupled in a day. 
One noticeable recent development in the field of phosphonium based peptide 
coupling reagents has been the replacement of the 1- hydroxybenzotriazole portion of 
reagents (22) and (23), with the 7 -aza analogue (28) as reported by Carpino28'29. This 
has led to the postulation of the neighbouring group effect (29) being an important 
factor in the increased reactivity of this class of compound. 
N . / 







The major benefits claimed are enhanced coupling yields and lower levels of 
racemisation in comparison to (22) and (23), together with the visual indication of 
reaction endpoint by a yellow to colourless colour change during coupling. 
One further class of reagents which are related to phosphonium salts are the carbon 
analogues or uronium salts (30) described by Knorr30. These reagents show a similar 




PF6- \7 N PF6- 
^± 
N(CH3)2 --- O-=Ñ(CH3)2 
N(CH3)2 N(CH3)2 
(30) 
1.3.3.4 Symmetrical Anhydrides 
The symmetrical anhydrides of Na protected amino acids are easily prepared from 
two equivalents of amino acid derivative and one equivalent of carbodiimide 
(Scheme 9). They are generally fairly stable crystalline solids, but are more routinely 
pre -formed automatically during synthesis and used without isolation. 
0 
11 DIC lo 
O N 
3 




Pre -formed symmetrical anhydrides (PSA) have found widespread use in Fmoc 
SPPS due to their ease of preparation, reactivity and the unambiguous aminolysis 
they produce on reaction with a free amino group. The major drawbacks to their use 
is the fact that one equivalent of expensive Na protected amino acid is discarded and 
also that certain amino acid side chains give serious side reactions with 
carbodiimides e.g. asparagine /glutamine - dehydration to nitrile (Section 1.3.3.2) and 
histidine - racemisation31. 
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1.3.3.5 Active Esters 
As stated previously (Section 1.3.3), the aminolysis of an Na protected amino acid 
requires that the acyl carbonyl is activated by an electronegative substituent X 
(Scheme 3). Many types of active ester, which fulfil this requirement, have been 
reported32 for the generation of amide bonds, although relatively few have been 
successfully applied to automated solid phase peptide synthesis. Those which are 
currently available commercially, are generally esters of phenols or other similar 
acidic functionalities which give stable crystalline derivatives e.g. esters of 1- 
hydroxybenzotriazole (HOBt)33 (31), pentafluorophenol (Pfp)34 (32) and 3,4- 
dihydro-3 -hydroxy-4-oxo- 1 ,2,3-benzotriazine33,35 (33). 
RCO-O 
N 
RCO-O-N N I N N N 
(31) (33) 
RCO-O 
Because all of these active esters are less activated than the active intermediates 
discussed previously, side reactions which normally accompany the coupling step are 
less of a problem with this class of compounds. 
1.4 Acidolytic Cleavage - Mild Acid Cleavage 
At the completion of the assembly phase of SPPS, it is common practice to 
simultaneously deprotect the majority of side chain protecting groups and remove 
the peptide from the resin in a single step. This process usually involves generation 
of stable cations which can attack electron rich side chains of the amino acids 
17 
tryptophan , tyrosine and methionine. Additives such as water, 1,2- ethanedithiol 
(EDT), thioanisole, anisole and phenol can be added to trifluoroacetic acid (TFA) 
based cleavage mixtures in order to minimise these side reactions, by scavenging the 
TFA liberated carbocations before they can interact with susceptible side chains. 
These scavengers act not only by trapping carbocations, but also as nucleophiles in 
the cleavage step by shifting the mechanism of cleavage from SN1 towards SN2 for 
certain less acid labile protecting groups e.g. 2,2,5,7,8- pentamethylchroman -6- 




















NH = C-NH^^^' 
NH 2 
NH=C-NH 
Scheme 10. Acidolytic cleavage of Arg(Pmc) 
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As a general rule, cleavage of peptides which do not contain sensitive amino acids 
and only require removal of t -butyl based protecting groups, can be accomplished by 
treating with 95% TFA/5 %H20. But for sequences which contain these 
aforementioned residues or trityl (35) , 4,4'- dimethoxybenzhydryl (MBH) (36) and 
Pmc protected residues, carbocation scavengers must be included37. 




The cleavage of protecting groups at the final stage of synthesis has always been 
problematic and for the production of large peptides and small proteins, which 
contain large numbers of protecting groups, the final deprotection can often 
determine the whole strategy of the synthesis38. The cleavage conditions required to 
generate parent amino acid from a side chain protected derivative cannot be applied 
directly to the synthesis of large complex peptides, and it is for this reason that 
several groups have tried to ensure complete deprotection on acid cleavage by using 
strong acids. 
Both HF39 and TFMSA40 have been reported for cleavage from the resin and side 
chain deprotection, after assembly using Fmoc SPPS. TFMSA offers the added 
advantage that it is compatible with conventional laboratory glassware, is an easily 
handled liquid and its use in cleavage and side chain deprotection with respect to 
19 
Boc based chemistry has been well reviewed41,42 More recently Yajima et al have 
reported the use of trimethylsilylbromide (TMSBr)43 as a hard acid44 in combination 
with thioanisole as a soft nucleophile to effect complete side chain deprotection. This 
reagent efficiently removes all side chain protecting groups commonly used in Fmoc 
SPPS (with the exception of the acetamidomethyl derivative of cysteine) including 
benzyl esters and ethers, pMeBz(Cys) and Z(Lys). After cleavage using TMSBr/TFA 
the peptide is then isolated, by precipitation with diethyl ether, as the intermediate 
trimethylsilylated compound which is readily hydrolysed and desalted by size 
exclusion chromatography in the presence of acetic acid to give the pure deprotected 
product. Yajima and co- workers also reported that TMSBr/TFA quantitatively 
reduces Met(0) to Met and that the amount of succinimide formation found in a 
model sequence was reduced from 4.6 %, found when using TFMSOTf/TFA, to nil 
when using TMSBr/TFA. This reagent is therefore an attractive alternative to TFA 
for the cleavage of peptides synthesised using Fmoc SPPS. 
20 
1.5 Chemical Synthesis of Proteins 
Six years after the initial publication outlining the solid phase method of peptide 
synthesis', Gutte and Merrifield reported the first solid phase synthesis of a protein45 
and, although the biologically active product was by no means homogeneous, this 
proved that it was possible to assemble such a complex molecule in a stepwise 
manner and that it would fold into its active form. Since that pioneering synthesis the 
solid phase synthesis of large peptides and small proteins has been the ultimate 
challenge of SPPS methodology. 
The intervening 20 or so years have seen improvements in both the chemistry and 
separation science which now make the production of homogeri ous, crystalline 
proteins by stepwise solid phase synthesis a realistic goal. In particular, the chemical 
synthesis of proteins and analogues containing residue specific labels and non -coded 
amino acids is now seen as a complementary approach to recombinant DNA 
techniques. This has most recently been exemplified by the synthesis and X -ray 
crystal structure determination of Kent's L- (Aba67,95,167,195)HIV -1 protease 
analogue46, using Boc SPPS, and the Fmoc SPPS and crystallisation of ubiquitin47,48 
and a closely related analogue49. 
The total chemical synthesis approach to such molecules demands highly optimised 
protocols, both during synthesis and purification, in order to produce the desired 
target molecule in pure form. Several important factors which influence the success 
of such syntheses have been identified. 
1. As a general rule the initial loading of the first amino acid onto the solid support 
should be lower than would normally be employed in the synthesis of a short peptide 
(i.e. <0.25mM/g of resin). 
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2. Each coupling must use an excess of activated amino acid derivative in order to 
force the coupling to completion and double coupling cycles are preferable. 
3. After each coupling step and before the subsequent deprotection of the Na 
protecting group, any remaining free amino groups must be "capped" by a suitable 
acetylating agent (e.g.acetic anhydride) before the next amino acid in the sequence is 
introduced. 
4. The progress of the synthesis must be monitored in order to assess the 
effectiveness of couplings and deprotections as well as the possibility of side 
reactions or mechanical failure during automated synthesis. 
5. At the completion of synthesis, after side chain deprotection and release from the 
resin, the crude cleaved protein should then be sequentially purified using a variety 
of techniques which allow differentiation between the desired sequence and any 
accumulated acylated truncation sequences. The protein should then be allowed to 
fold into its native form and purified to homogeneity under non -denaturing 
conditions. 
6. Finally the pure product must be thoroughly characterised using techniques such 
as amino acid analysis, isoelectric focussing, mass spectrometry and N- terminal 
sequencing, in order to confirm the composition and purity of the product. It is only 
once these criteria have been satisfied that the protein structure can be studied with 
any degree of certainty by either non -destructive techniques such as nuclear 
magnetic resonance (NMR) and X -ray crystallography, or by enzymatic degradation 
if applicable. 
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1.5.1 Chemical Synthesis of Proteins - Convergent Strategy 
An attractive approach to overcoming the inadequacies of stepwise SPPS as a 
method of protein synthesis, is the use of a convergent strategy in which smaller 
fragments of a protein are synthesised and purified separately before being coupled 
together to form the desired molecule. In principle, the advantage of this approach 
lies in the fact that the difference in size between product and reactants should allow 
easy purification of the target molecule. Although in practice, the low solubility of 
large protected peptide fragments in organic solvents has meant that few laboratories 
have used this approach successfully. 
An interesting variation on this convergent approach to protein synthesis has recently 
been reported by Schnolzer and Kent50 in which the two halves of the target 
polypeptide were synthesised incorporating a mutually reactive functional group in 
each segment. The N- terminal fragment contained a thioacid functional group at the 
C- terminus (37) (Scheme 11), whilst the C- terminal fragment incorporated an N- 
terminal alkyl bromide (38). The two segments (37) and (38) were then ligated 
together at pH4.3 in guanidine solution via an SN2 nucleophilic displacement to give 
a fully biologically active analogue of HIV -1 protease (39) containing a thioester 
pseudo -peptide bond at the ligation site. 
H.Prd Ilé0 -NHCH2COSH 
(37) 











This highly selective ligation reaction means that the coupling of the two fragments 
can be carried out with no need for side chain protection, even of cysteine residuesso. 
The main disadvantages of this method are due to the instability of the thioester 
pseudo peptide bond at physiological pH and the fact that this structural motif results 
in the introduction of an altered backbone into the protein. Whilst these factors are 
unimportant in the case of HIV -1 protease, the general application of this method 
remains to be demonstrated in other systems. 
Kent's group have recently reported a further variation of their chemoselective 
ligation strategy which may prove to have all the advantages of the thioester method 
without the previously stated disadvantages. Chemoselective ligation to give a native 
peptide bond has been reported for the synthesis of IL -8 (72 residues)51. The ligation 
reaction (Scheme 12) involves nucleophilic attack by the thiol group of an N- 
terminal cysteine residue of one fragment (40), the C- terminus of the target protein, 
on a second fragment (N- terminus of target protein) which contains a carboxy 
terminal thioester functional group (41). Displacement of the thioester results in the 
formation of an intermediate S -acyl compound (42), which spontaneously rearranges 
to give a native amide bond and the regenerated thiol of the cysteine residue next to 
the ligation site in the product protein (43). Again this ligation reaction is carried out 
in guanidine solution and at pH 7.6 with no need for any side chain protection, even 
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NH3 +11,-8 1-75+ CO2 
SH SH SH 
(43) 
Scheme 12. Schematic diagram of chemoselective ligation to give native amide bond 
This method offers a departure from conventional approaches towards the chemical 
synthesis of proteins and should allow construction of large synthetic proteins ( >200 
amino acids) in a controlled and reproducible manner and in yields which should 
rival recombinant DNA technology. 
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CHAPTER TWO : CHEMICAL SYNTHESIS OF MBD FROM MeCP2 
2.1 DNA Methylation 
5- Methyl- 2'- deoxycctidine (m5dC) (44) is the sole methylated nucleoside found in 
eukaryotes52 and one of several found in prokaryotes53. Although the exact function 
of DNA methylation in higher eukaryotes is not fully understood, DNA methylation 
has been implicated as being an important factor in the control of a number of 
biological processes. These include transcription54, developmental regulations, 
mutagenesis56, X inactivation57 and chromatin organisation58. It has also been 
suggested that abberations in cytosine 5- methylation may play a role in human 
genetic disease59. 
Methylation of DNA at the polynucleotide level is catalysed by DNA cytosine -5- 
methyltransferase (m5C- Mtase) enzymes which mediate delivery of a methyl group 
from S- adenosyl -L- methionine (SAM) to the 5- position of a cytosine residue in 
DNA. The mechanism employed by m5C -Mtase's as proposed by Verdine et aí52 is 
given in Scheme 13. 
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Scheme 13. Mechanism of enzyme mediated cytosine methylation52 
The first step of the reaction involves attack of a cysteine thiolate on C6 of the 
cytosine substrate (45) with simultaneous protonation at N3 by an enzyme- derived 
acid to give an enamine covalently attached to the enzyme (46). The enamine then 
attacks the methyl group of S- adenosyl -L- methionine (SAM), transferring it to C5 
(47) (Step 2, Scheme 13). Abstraction of the proton at C5 (Step3) by some basic 
residue on the enzyme again yields an enamine (48) which then undergoes conjugate 
elimination (Step 4) to yield the product (44) and the re- generated m5C- Mtase. 
Verdine and co- worker proposed60 that because protons were transferred to and from 
N3 of the cytosine residue, and also that co- valently linked duplexes were still 
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methylated by the enzyme, that the Watson -Crick GC base pair must be disrupted to 
allow extrusion of the cytosine substrate to an extra -helical position (Figure 1). 
Figure 1. Model for helical distortion during 
m5C -Mtase catalysed methylation of DNA 
This proposed model was subsequently confirmed by determination of the X -ray 
crystal structure of a covalent reaction intermediate from the reaction of a m5C- 
Mtase, SAM and a 13mer DNA duplex containing 5- fluoro -2'- deoxycytidine (FdC) 







2.2 Synthesis and Structural Studies of the Methyl -CpG Binding Domain 
from the Chromosomal Protein MeCP2 
2.2.1 General 
There have been two possible explanations as to how DNA methylation serves as a 
signal for molecular recognition processes which result in the aforementioned 
biological changes (Section 2.1). One is that certain species, such as transcription 
factors, may be unable to bind to their normal recognition sequences when they 
contain methylated CpG's. However the transcription factor Sp 1 has been shown to 
bind equally well to both methylated and non -methylated DNA and can indeed 
stimulate transcription from a methylated binding site62. 
The second possibility is that nuclear proteins which bind to methylated CpG, could 
form protein -DNA complexes which do not allow access to transcription factors or 
other species which normally recognise the "naked" DNA. Recently, several proteins 
have been identified which show a high affinity for methylated DNA and this has 
given support to the indirect mechanism. 
Two chromatin associated proteins which bind to double stranded DNA containing 
symmetrically methylated CpG's have recently been reported and are referred to as 
methyl -CpG- binding proteins or MeCP's. MeCP1 requires at least 12 methylated 
sites for efficient binding63 whereas the second member of this family of proteins, 
MeCP2, can bind specifically to a single methyl -CpG pair. Neither protein requires 
specific sequences to either side of the symmetrically methylated CpG sequence in 
double stranded DNA, and this highly specific binding distinguishes them from other 
proteins which bind to methylated DNA64,65. 
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As well as differing in the number of methyl-CpG's required for binding, MeCP -1 
and MeCP -2 exhibit functional differences. There is some evidence that MeCP -1 can 
inhibit transcription from methylated promoters both in vitro and in vivo54, whilst 
initial reports by Meehan and co- workers66 indicate that MeCP -2 is not involved in 
transcriptional repression. However, MeCP -2 may play a role in the protection of 
methylated genome DNA against nucleases, due to the fact that it is much more 
abundant than MeCP -1 and also due to its distribution in the genome66. 
MVAGMLGLRKEKSEDQDLQGLKEKPLKFKKVKKDKKEDKE 
GKHEPLQ P SAHH SAE PAEAGKAET SE S SGSAPAVPEASAS 
PKORRS I I RDRGPMYDDPTL PEGWTRKLKORK SGR SAGKY 
DVYL INPOGKAFRSKVEL IAYFEKVGDTSLDPNDFDFTVT 
GRGSP SRREQKPPKKPKS PKAPGTGRGRGRPKGSGTGRPK 
AAA SEGVQVKRVLEKS PGKLLVKMP F QA S PGGKGEGGGAT 
T SAQVMVI KR PGRKRKAEADP QA I PKKRGRK PG SVVAAAA 
AEAKKKAVKESS IRSVQETVLP IKKRKTRETVS I EVKEVV 
KPLLVSTLGEKSGKGLKTCKSPGRKSKES S PKGRS S SAS S 
PPKKEHHHHHHHAESPKAPMPLLPPPPPPEPQSSEDPISP 
PEPQDLS S S ICKEEKMPRAGSLESDGCPKEPAKTQPMVAA 
AATTTTTTTTTVAEKYKHRGEGERKDIVS S SNPRPNREEP 
VDSRTPVTERVS 
Figure 2. Deduced amino acid sequence of MeCP -2 (MBD underlined) 
The deduced amino acid sequence of MeCP -2 is shown in Figure 2. MeCP -2 is a 492 
amino acid 84Kd protein which is rich in basic residues and, although it contains 
short motifs which have been implicated in minor groove binding of A -T rich DNA, 
shows no extensive similarities to other DNA binding proteins67. Bird and co- 
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workers67 were able to show, by constructing deletion mutants of MeCP -2, that an 85 
amino acid section from the N- terminus of MeCP -2 (78 -162) (underlined in Figure 
2) was responsible for the specificity of the protein for methylated DNA. This 
methylated -CpG- binding domain, or MBD protein, has been overexpressed and 
shown to bind in vitro, as a monomer, to double stranded DNA containing a single 
symmetrically methylated CpG pair with an approximate dissociation constant of 
10-9M67. MBD has negligible affinity for either non -methylated or hemi- methylated 
DNA and the amino acid sequence of MBD contains no recognisable DNA binding 
motifs. 
In order to study the interaction of MBD with methylated DNA at the molecular 
level, sufficient amounts of protein for NMR studies were required. However, initial 
attempts to produce MBD using recombinant DNA technology gave only low levels 
of the desired protein which proved to be extremely insoluble, even at relatively low 
concentration in aqueous solution68. It was therefore decided to attempt the total 
chemical synthesis of MBD protein using batch stepwise Fmoc SPPS. 
2.2.2 Chemical Synthesis of MBD 
As has been stated previously (Section 1.5), the total chemical synthesis of a protein 
requires a different strategy from that normally employed for the synthesis of short 
peptide sequences. In particular the increased possibility of secondary structure 
formation during synthesis often leads to abrupt drops in coupling and deprotection 
efficiencies, which in turn may ultimately result in very low yield of the desired 
sequence along with the inherent problems of isolation of the protein from the 
accumulated truncation sequences at the completion of the assembly. It was for these 
reasons that an initial trial synthesis was attempted as a "scouting run" which, it was 
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hoped, would highlight any sections of the sequence which required extended 
couplings or deprotections in order to optimise the final synthesis. 
This first synthesis was undertaken on an initial substition of 0.15mM/g of 
Fmoc.Arg(Pmc) on 4- alkoxybenzylalcohol functionalised polystyrene resin (8) and 
utilising single couplings of 3.5 equivalents of preformed HOBt esters. All side chains 
were protected as described in the experimental notes (Chapter 7) with the exception 
of the carboxamide side chains of asparagine and glutamine which were incorporated 
unprotected. The coupling efficiencies for each amino acid residue were estimated 
by automatically taking an aliquot of the deprotection solution, containing the 
generated fulvene -piperidine adduct (50) (Scheme 14), passing it through a UV 
detector set at 302nm and integrating the peak obtained69. 
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Thus, the on line coupling monitor showed a fall off in coupling efficiency over the 
regions corresponding to residues 69 to 56 and 41 to 25. The coupling efficiency (by 
UV of the deprotection peak) for this trial synthesis dropped to <10% of the initial 
peak height for the first amino acid on the resin, and therefore no attempt was made 
to isolate any of the expected sequence. 
The 85 amino acid sequence of MBD was then resynthesised using optimised 
coupling cycles over the areas which had proved to be problematic during the initial 
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synthesis. At the completion of the assembly phase of this optimised synthesis the 
Fmoc deprotection peak corresponding to the penultimate residue, indicated an 
overal coupling efficiency of approximately 70% with respect to the value obtained 
for the deprotection of the first residue. The N- terminal Fmoc group was left on at 
the end of the synthesis and the resin bound product was then treated with a mixture 
of acetic anhydride/ HOBt/ DIEA in a sonic bath, in order to "cap" any remaining 
free amino groups present on the resin. 
One of the main obstacles to the stepwise chemical synthesis of proteins, is the 
difficulty in purification of the desired sequence from the accumulated deletion 
sequences which form, due to incomplete couplings during synthesis. Several 
methods have been reported, which allow differentiation between the target sequence 
and any acetylated truncations present, by derivatising the N- terminus of the protein 
with a group which then allows either affinity type binding70,71 or covalent 
attachment72 to a solid support. The acetylated truncation sequences are then simply 
washed away, before the desired sequence is released from the solid support in pure 
form. Recently, Ramage et aP3'74 have reported the use of the base labile Na 
protecting group tetrabenzo( a, c, g,i)fluorenyl -17- methoxycarbonyl (Tbfmoc) (51) for 
the purification of synthetic peptides and small proteins. This method allows rapid 
and efficient separation of the Tbfmoc- peptide from any acetylated truncation 
sequences, due to the high affinity of the polycyclic aromatic label for porous 
graphitised carbon (PGC)73,74. Alternatively, the hydrophobic nature of the Tbfmoc 
group and its specific UV absorbance at 364nm can be exploited to simplify peptide 
purification by RP -Hplc. This method was therefore chosen to help aid the 
purification of the synthetic 85 amino acid MBD protein. 
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(51) X= NHR 
(52) X= Cl 
After removal of the N- terminal Fmoc group with 20% piperidine in DMF, the 
Tbfmoc group was introduced by treatment of the resin bound peptide with 
chloroformate (52)75 and DIEA in dichloromethane with sonication. After three 
hours the resin bound Tbfmoc Na protected peptide was thoroughly washed with 
dichloromethane before being dried, cleaved from the resin (TFA, water, EDT, 
thioanisole,phenol ), precipitated with diethyl ether and gel filtered (Sephadex G50, 
30% AcOH). Figure 3(a) shows the analytical RP -Hplc trace of the crude Tbfmoc- 




HPLC of crude cleaved Tbfmoc MBD 
Tin1. Mtn) 
b HPLC of Pure MBD after removal of 
Tbfmoc protecting group 
15 
Tm. (n.n1 
Figure 3. HPLC traces of (a) crude cleaved MBD and (b) pure MBD protein after 
removal of the Tbfmoc group 
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Semi -preparative Hplc, monitoring at 364nm, gave pure Tbfmoc -MBD which was 
then dissolved in guanidine solution and treated with piperidine to remove the 
Tbfmoc group, before being neutralised (AcOH,0 °C), desalted by gel filtration 
(Sephadex G50, 30% AcOH) and purified to homogeneity by RP -HPLC (Figure 
3(b)). 
A comparison of the crude Tbfmoc -MBD and the purified protein (Figure 3) 
illustrates that the deletion sequences, which do not react with reagent (52), elute at 
the same retention time on Hplc as the pure MBD protein. Hence, without use of the 
Tbfmoc group to aid purification, Hplc purification on its own would have been 
unable to separate the truncated sequences from the desired product. 
Figure 4 shows an SDS polyacrylamide gel of the crude cleaved MBD, Tbfmoc 
purified material and the deletion sequences which did not react with the reagent 
(52). It is clear from these results that the truncations (lanes 4 and 5) 
of material of molecular weight < 6380 Da.(molecular weight standards lanes 1 and 
8). Therefore, reaction of (52) with the free amino group of the resin bound MBD is 
almost quantitative, due to the fact that there are only trace amounts of MBD visible 
in lanes 4 and 5. 
1 2 ..3 4 5 :6 .7 "8 
Figure 4. SDS Phastgel (Homogeneous 20), Lanes 1 +8 Mwt.Std. 
Lanes 2 +3 Crude cleaved MBD. Lanes 4 +5 Truncations. Lanes 6 +7 Pure MBD 
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From an initial loading of resin bound Fmoc.Arg(Pmc) of 0.14mM(1.0g), the 
synthesis yielded 2.28g of fully protected resin bound product. Typical yields of 
protein from the above synthesis gave 30 -35mg of pure protein from a 0.5g portion 
of the fully protected resin bound product. This equates to an overall yield of 13% 
for over 170 chemical steps. 
The purified MBD protein has also been fully characterised by mass spectrometry 
(Figure 5)76,amino acid analysis (Table 1) and automated Edman degradation77 
confirmed that the first twenty six residues were in the correct sequence. 
T. i ' ent.: N'ti cg: 
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Figure 5. Laser desorption time of flight mass spectrum of synthetic MBD76 




















































Table 1. Amino acid analysis of synthetic MBD protein 
2.2.3 Binding of Synthetic MBD to Methylated DNA 
The simplest and perhaps the most widely used method for investigating protein - 
nucleic acid interactions is by use of the gel retardation or band -shift assay78. It is 
based on the observation that binding of a protein to a DNA fragment usually leads 
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to a reduction in the electrophoretic mobility of the fragment in non -denaturing 
polyacrylamide or agarose gels. 
Figure 6 shows such a band -shift assay obtained for native MBD when incubated 
with the DNA sequences indicated. This shows that binding of MBD to methylated 
DNA requires m5dC (44) to be present symmetrically in the CpG sequence. This 
assay, when repeated with chemically synthesised MBD, gave identical results to 
those obtained for the expressed material68, thus proving that both samples had the 
same affinity and specificity for DNA sequences containing a symmetrically 
methylated CpG sequence. 
AB17-CG AB17-MG AB17-MM AB17-hemi. 
MBD(ng) 0 2 10 
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Surprisingly the chemically synthesised material was much more soluble in aqueous 
solution than the expressed protein, although comparisons of synthetic and native 
protein both by band -shift (Figure 6) and denaturing SDS PAGE (Figure 7)79 seemed 
to indicate that both materials were essentially identical. One possible explanation 
for the differing solubilities of the synthetic and native MBD could be due to the fact 
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that one is folded whilst the other is denatured. Alternatively the solubility of the 
synthetic MBD may be due to residual trifluoroacetate from Hplc buffers, which 
results in solutions of acidic pH when the protein is dissolved in water and thus 
solubilises the basic protein (pI 10.7). 
« -.' +it...... 
...r. .. .. ..,... .. _ 
it* 
Recombinant MBD Synthetic MBD Synthetic MBD M.Wt. Std. 
Figure 7. Comparison of synthetic and native MBD by SDS- PAGE79 
2.2.4 Structural Studies on Synthetic MBD 
One of the major goals in the field of protein synthesis, is to be be able to deduce the 
three dimençional structure of interesting target molecules. Once the desired protein 
is obtained pure in milligram amounts, this can be approached by utilising a variety 
of methods such as circular dichroism(CD), nuclear magnetic resonance (NMR) and 
X -ray crystallography. 
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2.2.4.1 Circular Dichroism (CD) 
CD is useful in providing quantitative information in regard to the secondary 
structure content of an asymmetric molecule, such as a folded protein. The technique 
utilises the ability of chiral substances to absorb the right and left hand components 
of plane polarised light to different extents. This results in the transmitted light 
emerging from the protein sample being rotated by an angle 0, relative to the 
polarisation of the incident light. Typical protein spectra are obtained in the region of 
260 - 190 nm where the most abundant chromophore is generally the amide bond. 
Secondary structure elements such as a- helices, (3- sheets and (3 -turns all give distinct 
CD spectra80 and numerical values of the stuctural content are normally obtained 
using the CONTIN procedure81. This uses a combination of the CD spectra from 
reference proteins, whose secondary structure elements are known from crystal 
structure data, for a direct comparison of secondary structure elements in proteins of 
structure. 
CD measurements on synthetic MBD were carried out at the Scottish CD Facility at 
Stirling University82 and the results are given in Figure 8 and Table 2 below. 
C.D.Spectrum of MBD 
509e TFE 100%rH20 
Y.e%e!nath (non 
L.D. measurements were carried out at the Department of 
Biological and Molecular Sciences . University of Stirling . 
Figure 8. CD spectra of synthetic MBD in H2O and H2O/TFE (1:1) 
200.0 
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Solvent a -Helix 13 -Sheet Remainder 
H2O pH4.5 8% +/- 0.43% 51% +/- 0.52% 41% +/- 0.83% 
50% [FE 30% +/- 1.1% 52% +/- 1.1% 18% +1- 2.0% 
Table 2. Predicted structural content of synthetic MBD 
from CD spectra in the solvents indicated 
The sample was prepared simply by dissolving the pure synthetic MBD in water to 
give a solution of pH 4.5. The CD spectra obtained from this sample (Figure 8) 
indicated only low levels (8 %) of a- helical structure, although addition of 2,2,2 - 
trifluoroethanol (TFE) resulted in induced structure formation which correlated to 
30% a- helix. This increase in helicity occurs with no loss of (3-sheet structure as 
calculated by the CONTIN81 secondary structure prediction procedure. However, 
previous studies on the ubiquitin system83,84 have also given increased a- helical 
content in the presence of TFE, although the validity of these figures remains to be 
confirmed by other methods. 
None the less, it was encouraging that the synthetic protein seemed to have some 
degree of structure without any attempt being made at folding and, as had been 
proved by gel retardation assay, the synthetic MBD was sufficiently folded to bind to 
methylated DNA. Hence it is possible that the protein domain is only loosely 
structured on its own in solution, but that binding to its recognition site stabilises 
some of the more flexible regions of the protein due to electrostatic interactions with 
the methylated DNA. 
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2.2.4.2 Nuclear Magnetic Resonance (NMR) 
NMR spectra of synthetic MBD were obtained from a sample of 25mg at pH 6.3 and 
at various temperatures. At pH values above this the protein sample very quickly 
aggregated, and even at pH 6.3 the instability of the sample resulted in poor quality 
spectra. Although these spectra were not of the quality required to allow sequential 
assignment using standard techniques85, they did indicate that the synthetic protein 
was spontaneously folding in solution. 
Recently, the solution structure of recombinant MBD has been solved86. An analogue 
of MBD, extended at the N- terminus with a sequence of amino acids to allow 
affinity purification and also extended at the C- terminus, was overexpressed and 
purified in sufficient quantities to allow the determination of its three dimensional 
structure in solution (Figure 9). 
MBD from MeCP2 
(450 inter -residue NOEs) 
54 
N (18) C(86) 
Figure 9. Solution structure of recombinant MBD86. 
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The core of the structure is made up of a short a -helix and 3 [3-strands, whilst the 
remainder of the backbone consists of relatively unstructured loops. Both the N and 
the C- terminal regions of the structure could not be resolved and are probably 
flexible in solution when not bound to methylated DNA. 
A comparison of the synthetic and recombinant protein by 1D NMR (Figure 10) 
clearly illustrates that both adopt a similar structure in solution. Both spectra have 
the same pattern of methyl resonances between 0- 0.6ppm, where the upfield shift is 
due to their proximity to electron rich aromatic residues within the protein core. 
Furthermore, both proteins exhibit similar paterns of signals around 6ppm, due to 
increased shielding of an aromatic residue in the core, as well as between 7.5 and 
9.7ppm due to the backbone amide protons of the folded protein. 
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Figure 10. NMR spectra of synthetic MBD (top) and recombinant protein 
incorporating the MBD domain (bottom). 
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2.2.4.3 NMR Studies of MBD- Methylated DNA Complex 
Whilst it was clear that both the synthetic and recombinant proteins bound strongly 
to methylated DNA (Figure 6). The limiting factor to the study of such a complex in 
solution, is the solubility of the complex at a pH where it is stable. The synthetic 
MBD protein was found to be extremely insoluble at pH7 and above. Therefore as a 
feasibility study, the binding of the synthetic protein to methylated DNA was 
investigated by bandshift assay after incubating the protein and DNA together at 






DNA sequences (53) and (54) were synthesised (OSWEL, University of Edinburgh) 
and purified using the method of Ramage and Wah187a by labelling the 5' end of the 
oligonucleotide with 4- (17- tetrabenzo[a,c,g,i] fluorenylmethyl )- 4',4 "- dimethoxytrityl 
chloride 5587b. The purified oligonucleotides were then annealed to form the 
corresponding duplex which was subsequently used in the band shift assay (Figure 
10). This confirmed that at pH 6.3, the protein would still bind to the methylated 
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DNA. Further studies are currently in progress to enable NMR studies on the 
protein -DNA complex, in an attempt to solve the structure of the methylated DNA 
binding domain of MeCP2 when bound to methylated DNA. 
Figure 10. Bandshift assay showing synthetic MBD binding to DNA duplex of 
53 +54 after incubation at pH 6.3 
2.2.4.4 Crystallisation studies on MBD 
As part of a collaboration between our group and the laboratory of Dr.L. Sawyer 
(Department of Biochemistry, University of Edinburgh), crystallisation studies have 
been carried out on both the synthetic MBD and the protein- methylated DNA 
complex. Extensive investigations have failed to produce any crystalline MBD 
protein on its own88. However, initial results of crystal screening carried out on the 
protein -DNA complex have yielded micro -crystals (Figure 11). Although these 
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micro -crystals are too small to be useful for structure determination, efforts are being 
made to increase the size of the crystals by varying the conditions of crystallisation88. 
Figure 11. Micro -crystals obtained by hanging drop experiment from synthetic 
MBD protein- synthetic methylated DNA mixture. 
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CHAPTER THREE : RESTRICTION ALLEVIATION PROTEIN 
3.1 General 
Bacteria use three kinds of methylation to protect their DNA against the action of 
restriction enzymes. As well as 5- methy1- 2'- deoxyctidine (44), which is widespread 
in eukaryotes, lower organisms have been found to contain DNA methylated at the 









The E.Coli strain K12 chromosome encodes a type I endonuclease known as EcoK, 
which is a complex multifunctional system made up of three subunits. The subunits 
are coded for by three contiguous gene sequences known as hsdR (host specific for 
DNA restriction), hsdM (modification) and hsdS (specificity)90, which are 
responsible for the nuclease action, methylation and sequence specificity of the 
endonuclease. 
When foreign DNA from an infecting phage enters bacterial cells, a process called 
host controlled restriction is initiated by the restriction endonuclease EcoK. In this 
process the EcoK acts either as a methylase or a nuclease, and the mode of action is 





Figure 9. EcoK recognition site 
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If the recognition site is methylated at the adenines marked with an asterisk (Figure 
9), the enzyme recognises the DNA sequence as being host derived and there is no 
reaction. If neither adenine is methylated the enzyme recognises this as foreign 
DNA, which signals the enzyme to act as a nuclease and the DNA is cleaved at a site 
distant from the recognition site. When the recognition site is hemimethylated, i.e. 
methylated at only one of the asterisked adenines (Figure 9) as would be the case 
immediately after replication, the EcoK enzyme is triggered into its methylase mode 
and the unmodified adenine is methylated. 
Several phages are known to protect themselves against host controlled restriction by 
encoding a protein which completely blocks the EcoK activity91, but phage X utilises 
a different mechanism in order to protect its unmodified genome. Zabeau et al92 
were the first to report mediation of restriction by the ral gene product of phage X 
and also the location of the ral gene in the X genome, although SDS -PAGE failed to 
reveal the expected product of the ral gene. Determination of the ral gene sequence93 
identified a 66 amino acid protein as the ral gene product which will subsequently be 





Figure 10. Deduced amino acid sequence of Ral 
Loenen and Murray94 subsequently reported the cloning and expression of the ral 
gene product, which gave rise to a 1000 -fold reduction in restriction and a 100 -fold 
increase in modification in vivo. However, attempts to produce Ral protein in 
amounts sufficient for characterisation and in vitro assay of the postulated action of 
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ral have proved unsuccessful95. Therefore, in order to investigate the action of Ral at 
the molecular level it was decided to attempt the total chemical synthesis of the 66 
amino acid protein deduced from the coding sequence (Figure 10). 
3.2 Choice of Cysteine Protection in Protein Synthesis 
Perhaps one of the most difficult trifunctional amino acid residues to deal with 
during the chemical synthesis of polypeptides is cysteine. The stepwise SPPS of 
cysteine containing proteins poses added problems due to the fact that some proteins 
require the cysteine residues to be in the free thiol form, while others form 
disulphide bonds between cysteine residues in order to stabilise secondary /tertiary 
structural conformations. 
The choice of Fmoc -cysteine derivative will vary depending on the synthetic 
strategy. However, synthesis of cysteine containing peptides usually involves either 
cleavage of the thiol protecting group as the peptide is removed from the solid 
support, or later by an orthogonal method once the polypeptide has been purified to 
some extent. Alternatively, a combination of temporary and semi -permanent cysteine 
protecting groups offers the possibility of regioselective disulphide formation96. 
Opinion seems to be divided on the best approach towards the batch SPPS of 
cysteine containing proteins. Boc based strategy has in the past relied mainly on 
temporary thiol protection which is removed on cleavage from the resin. The crude 
protein can then be folded and disulphides formed using a variety of techniques97, 
before being purified to homogeneity. This approach has been successfully 
demonstrated for the synthesis of hTGF -a98 (50 residues, 3 disulphide bridges), 
Interleukin -399 (140 residues, 2 disulphide bridges), Interleukin- 851 "00 (72 residues, 
2 disulphide bridges) and neutrophil activating peptide 2100 (70 residues, 2 
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disulphide bridges). 
The Fmoc based stepwise SPPS of large, cysteine containing polypeptides has on the 
other hand relied on the use of either the semi -permanent acetamidomethyl (Acm)1 01 
(55) protecting group, as described for the synthesis of hTGF -a102 (50 residues, 3 
disulphide bridges) or, a combination of Acm (55), with the semipermanent Tacm 
(56) and t -Butyl (57), as reported recently by Akaji et al for the synthesis of human 
insulin96 (51 residues, two peptide chains, 3 disulphide bridges). It cannot be stressed 
too strongly that a pre- requisite for the use of such a regioselective disulphide bridge 
forming strategy is that in subsequent chemical manipulations, the disulphide bridge 
or bridges are not exposed to conditions which promote disulphide exchange, 
scrambling, cleavage or modifications °3. 
H 
/NIr 










3.3 Chemical synthesis of the ras gene product of phage a, 
As has been stated previously (Section 3.1), some proteins require free thiols for 
biological activity, whilst others require disulphide bridges. In the case of Ral, little 
was known about ither the cysteine residues were reduced or disulphide bridged, 
although initially it was proposed95 that Ral contained a putative zinc finger -like 
motifs °a The thiols in Ral protein would therefore need to be present in the reduced 
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state in order to be able to co- ordinate tetrahedrally to a Zn2+ ion. 
Ral has subsequently been chemically synthesised four times, and each time the thiol 
protection has been varied in order to assess the best general approach for the 
synthesis of multiple cysteine containing proteins. The various synthetic approaches 
are discussed in the following chapters. 
3.3.1 Synthesis A - Cys S- StButyl protection. 
For the initial synthetic strategy of Ral, it was hoped that by using the acid and base 
stable t- butylsulphenyl (StBu) derivative (Scheme 14), it would be possible to purify 
the protein with the cysteine thiol groups fully protected. Then, as the final step it 
was planned to effect removal of the StBu cysteine protection by treating the pure 
protein with thiolsio5 or phosphineslo6 (Scheme 14). 
H. -]-- r-OH 
0-1-1 S P R"3 
PR" rThk S/ 3 S H+ 
RNHCHCOR' RNHCHCOR ' -tBuSH RNHCHCOR ' OPR 3 
Scheme 14. Removal of StBu group from cysteine by the action of 
trialkylphosphine /water. 
Starting from an inital functionality of 0.2mM resin bound Fmoc alanine, the desired 
sequence (Figure 10) was assembled on an Applied Biosystems 430A peptide 
synthesiser. All residues were treble coupled, with the exception of glycine which 
was single coupled via the symmetrical anhydride. Monitoring of the coupling 
efficiency during synthesis by UV (Section 2.2.2), indicated a low coupling of 
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lysine60 to glutamine61, although the remainder of the synthesis proceeded without 
further major drops in coupling. 
The cysteine protected protein was obtained by acidolytic cleavage using a mixture 
of TFA, EDT, phenol and water for five hours under an atmosphere of nitrogen, 
followed by evaporation of the TFA and trituration with diethyl ether to give the 
crude protein which was isolated by filtration. The crude protein was then applied to 
the top of a column of sephadex G -50 and eluted with aqueous acetic acid (30 %). 
The protein containing fractions were then pooled and lyophilised to give crude 
StButyl protected Ral protein. This material proved to be only slightly soluble in 
aqueous solution and when analysed by Hplc (Figure 11a), eluted as a broad peak 
which suggested the presence of several similar species. In an attempt to improve the 
solubility of the material, the hydrophobic StBu cysteine protecting groups were 
removed by treating a solution of the protected protein in 95% trifluoroethanoll5% 
water with tributylphosphine (Scheme 14). However, the crude fully reduced protein 
obtained remained only sparingly soluble in aqueous solution and gave no real 








Figure 11. Hplc analysis of crude (a) StButyl protected and (b) reduced Ral from 
synthesis A 
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Attempts to further purify this material by ion exchange chromatography failed to 
give any separation as most of the material failed to bind to either cation or anion 
exchangers at various pH values, but simply eluted in the void volume. However, a 
sample of this crude synthetic Ral protein was subsequently used to raise anti -Ral 
antibodies, which were used to monitor expression of recombinant Ral from plasmid 
pGK4 (Figure 12) by western blot analysis (Figure 13). This then allowed 
comparison of the synthetic and recombinant material (Section 3.3.2.1). 
Lane 
fd -t.t. 
Figure 12. Diagram of pGK4 plasmid 
1 2 3 4 5 6 7 8 
Ral 
Lanes 1 &2 - products from plasmid without Ral gene 
Lanes 3 &5 - products from plasmid pGK4 before heat induction 
Lanes 4 &6 - products from plasmid pGK4 after heat induction 
Lanes 7 &8 - synthetic Ral 
Figure 13. Western blot of synthetic and recombinant Ral (from pGK4) 
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3.3.2 Synthesis B - Cys(Acm) protection 
Insolubility of synthetic peptides can be due to many primary and secondary 
structural factors such as isoelectric point or aggregation at high concentration. 
However, in the case of Ral it was felt that the insolubility of the fully reduced crude 
protein, obtained from synthesis A, could only mean that cleavage from the resin 
with TFA had not removed all of the side chain protecting groups incorporated 
during the assembly phase. One notoriously difficult group to remove using TFA is 
the 4,4'- dimethoxybenzhydryl (MBH) group (36) used to block the carboxamide 
side chains of asparagine and glutamine, of which Ral contains eight in total. 
Funakoshi et aí107 have reported the use of trimethylsilyl bromide (TMSBr)/TFA to 
effect final cleavage and side chain deprotection of human pancreastatine -52 (52 
residues, 6 of them glutamine). However, the choice of cleavage conditions also 
dictates the synthetic strategy, as the only commonly used Fmoc cysteine derivative 
which is stable to TMSBr/TFA43 is the acetamidomethyl101 (Acm) derivative (55). 
Ral was therefore resynthesised using Acm protected cysteine and optimised 
synthetic cycles in order to overcome the areas of the synthesis which had proved 
problematic during synthesis A. 
The first twelve residues (55 -66) were coupled in a glass vessel, immersed in an 
ultrasound bath, and connected to the ABI430A peptide synthesiser to allow delivery 
of reagents. The protected peptide -resin was then transferred back into a 
conventional reaction vessel, before the assembly was allowed to continue until the 
end of the synthesis. At the completion of the assembly phase, the N- terminal Fmoc 
group was removed by treatment with piperidine and replaced by the 
afforementioned Tbfmoc group (51)73'74. The Tbfmoc labelled, Acm protected 
protein was then cleaved from the resin by treatment with 
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TMSBr /EDT /thioanisole /m- cresol/TFA for 5 hours at 0 °C, under an atmosphere of 
dry nitrogen and protected from the light. After rapid evaporation of the TFA and 
precipitation with diethyl ether, the crude Tbfmoc Acm- protected Ral protein was 
applied to the top of a column of sephadex G -50 and eluted with aqueous acetic acid 
(30%). The fractions containing Tbfmoc labelled protein were then pooled (Figure 
14a) and the pure Tbfmoc Acm -protected Ral was isolated by Hplc (semi -prep 
Vydac C18, A364nm). Pure Acm protected Ral protein was then obtained after 
removal of the Tbfmoc group with piperidine and isolation of the protein derivative 
by Hplc (Figure 14b). The pure cysteine protected protein was then characterised by 
mass spectrometry (Figure 15) and amino acid analysis. 
a 
J 
30 o 15 
Time (min) 
Figure 14. Hplc of (a) crude Tbfmoc Ral(Acm)4 after size exclusion 
chromatography and (b) pure Ral(Acm)4 
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Figure 15. Laser desorption time of flight mass spectrum of Acm protected Ral 
The stable Acm protecting group can be cleaved by reagents such as iodinelo8 
(Scheme 15) and thallium(III) trifluoroacetatei°9 (Scheme 16), which result in direct 
disulphide formation. 
CH3CONH~l CH3CONHI 
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However, both these reagents can adversely affect the electron rich side chains of 
tryptophan and methionine109,110, of which Ral contains seven (5 Met and 2 Trp). 
Also, due to the fact that we required the fully reduced form of Ral, in order to study 
its zinc binding properties, we were limited to the use of either silver 
trifluoromethanesulphonate111 or mercury (II) acetatel01 to remove the thiol 
protecting groups. Several proceedures for the cleavage of the Acm groups were 
examined using both the above reagents, and it was found that mercury acetate was 
superior for accomplishing complete removal of the Acm groups, as determined by 
mass spectrometry of the reaction products. 
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Hence the conditions used to remove the stable Acm groups on a large scale were by 
treatment of the pure Acm protected protein at pH 4.0 with mercury (II) acetate, 
followed by treatment of the resulting mercury salt of the protein with 
mercaptoethanol under denaturing conditions, before desalting by gel filtration 
(sephadex G -50, 30% AcOH). The fully reduced protein was then further purified by 
Hplc (Figure 16), before being characterised by mass spectrometry (Figure 17) and 
amino acid analysis. 
0 15 
Time (min) 
Figure 16. Hplc of pure reduced Ral protein after Acm removal. 
30 
Figure 17. Laser desorption mass spectrum of reduced Ral protein. 
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However, assay of the number of free thiols present in the protein using the method 
of Ellman112 gave only 1.0 thiol group per molecule. Eliman's reagent, 5,5'- 
dithiobis(2- nitrobenzoic acid) (DTNB) (58), reacts with thiol groups and releases a 
chromophoric anion (59), which can be exploited to enable spectroscopic 






However, this technique is limited to the detection of unhindered, solvent accessible 
thiols and hence some proteins are known to give lower than expected values113,114. 
N- terminal sequencing, on the other hand, confirmed not only that the first twenty 
two residues were in the correct sequence, but also that three of the four cysteine 
residues present in the Ral sequence were no longer Acm protected. This can be 
confirmed from the sequencing data due to the fact that prior to Edman degradation, 
the fully reduced protein was reacted with 2- vinylpyridine (60) (Scheme 17) to 
produce the pyridylethylated cysteine derivative (61). Compound (61) was 
subsequently identified as a product of the degradation by comparison with an 
external mixed standard containing (61). 
SH 
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3.3.2.1 Comparison of synthetic and recombinant Ral protein 
At this point in time, some recombinant protein, produced from plasmid pGK4 
(Section 3.3.1) and which cross reacted with anti -Ral antibodies, became available95 
and was compared with the synthetic protein. Figure 18 shows an overlay of the 
Hplc traces obtained for the recombinant protein, both before and after 
reduction/denaturation, and the synthetic material (N.B. both the reduced and fully 
Acm protected Ral co -elute on Hplc). The synthetic Ral eluted later than the 
recombinant material and, even after denaturation and reduction of disulphide 
bridges, the recombinant material was much less hydrophobic than the synthetic Ral, 
hence proving that the difference in retention times was not due to the recombinant 
material being folded differently. Therefore, in an attempt to identify if the 
recombinant material was actually the fully extended protein, it was subjected to 
analysis by N- terminal sequencing, amino acid analysis and mass spectrometry. 
Overexpressed Protein 
Overexpressed Protein + OTT 
l Synthetic Ral 
0 15 
Time (mm) 
Figure 18.Overlay of Hplc traces obtained for synthetic Ral compared to the traces 
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obtained for the recombinant protein before and after reduction. 
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Amino acid analysis of the recombinant material indicated that the value for alanine 
was lower than expected for the predicted sequence of Ral (Figure 10), which 
contains 5 alanine residues in the first 20 amino acids of the hydrophobic C- 
terminus. Attempts to perform N- terminal sequencing on the materials ss produced no 
degradation and therefore indicated that the N- terminus was blocked. However, mass 
spectral analysis of the recombinant proteins 5 before and after reduction and 
pyridylethylation (Figure 19) indicated that the material was of lower molecular 
weight than expected for the predicted sequence (7605amu), although it was clear 
that it did contain 4 cysteine residues due to the mass increase obtained on 
pyridylethylation (Figure 19). Hence from the combination of the preceeding 
evidence, the recombinant protein was identified as N-formyl Ral(1 -50) (requires 
MH += 5935, found = 5938.5) which had been isolated in an oxidised, disulphide 
bridged form. 
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Figure 19. Laser desorption mass spectrum of recombinant protein before (bottom) 
and after (top) reduction and pyridylethylation. 
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Attempts to introduce Co2+ ions into the protein, as a test of whether the protein 
adopted a classical zinc finger structure, failed to give any UV absorbance 
characteristic of a tetrahedral Co species116 with either the synthetic Ral protein or 
the reduced recombinant N- formyl(1 -50). Similarly, attempts to assay for the 
expected biological action of Ral gave no increase in the level of DNA modification 
for either the synthetic Ral or the recombinant material in the presence of various 
DNA substrates and the EcoK enzyme117. 
However, subsequent to this work being carried out, a sample of the synthetic Ral 
protein was re- analysed on a mass spectrometer76 of higher resolution to that used 
previously. The spectrum produced (Figure 20) clearly indicates that, although there 
is a large proportion of fully deprotected Ral present (requires MH+ = 7605, found 
MH+ = 7620), there is an approximately equal amount of mono -Acm protected Ral 
present (requires MH+ = 7676.1, found MH+ = 7694). This therefore suggested that 
although the cysteine protected protein had been obtained in pure form after Tbfmoc 
purification, the Acm group was not an optimal choice of protecting group due to the 
difficulties encountered in its attempted removal. 
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Figure 20. Laser desorption mass spectrum76 of synthetic Ral protein 
showing incomplete removal of Acm protection. 
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3.3.3 Synthesis C - Design of an enzyme cleavable cysteine protecting group and 
investigations of its application to the synthesis of proteins. 
As has been described above, our synthetic route to cysteine protected Ral protein, 
using Acm protecting groups and the Tbfmoc Na protecting group to aid 
purification, successfully results in the rapid isolation of the cysteine protected 
protein. However, the Acm group is not removed easily using literature 
procedures 'Km, as has been confirmed previously, both in these118,119 and other 
laboratories120,121. Therefore it seemed likely that if the thiol group of cysteine could 
be protected with a group which incorporated the stability and solubility properties 
of the Acm group, but which at the same time could be unambiguously removed 
under the mildest of conditions, then this would aid the synthesis of cysteine 
containing proteins. 
Recently there has been a renewed interest in the application of biocatalysts to the 
problem of functional group protection, for use in the field of peptide synthesis122 
and in other areas123,124. Because enzymes generally operate under physiological 
conditions and are highly discriminating in terms of stereochemistry, regio and 
chemoselectivity, enzymatic transformations offer an attractive solution to the 
problems of protecting group manipulation. At the present time, several enzymes are 
commercially available in pure, stable forms, some of which are supplied 
immobilised on a solid support to aid handling and recovery after use. 
Penicillin G acylase (E.C. 3.5.1.11) from Escherichia coli is an enzyme that has 
found wide spread use in the industrial preparation of semi- synthetic penicillins 
(Scheme 18). This enzme exists as an 80KDa heterodimer, which is made up of A 
and B polypeptide chains which contain 209 and 566 amino acids respectively, and 
has been shown to hydrolyse phenylacetyl amides with no specific requirements for 
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Scheme 18. Penicillin acylase catalysed reversible reaction 
Its use in peptide synthesis was first reported by Brtnik et a1127, who utilised the 
enzyme to remove the N£- phenylacetyl group from the side chain of lysine during 
the solution synthesis of vasopressin (9 residues). Greiner and Hermann128 
subsequently extended the use of penicillin acylase to deblock the side chain of 
phenylacetamidomethyl (Phacm) protected cysteine residues (62) during the 
synthesis of oxidised glutathione. The enzyme mediated cleavage reaction (Scheme 
19) initially generates an intermediate S- aminomethyl compound (63) (Scheme 19), 
on cleavage of the acyl component, which spontaneously hydrolyses to liberate the 
free thiol. The phenylacetamidomethyl (Phacm) protecting group was subsequently 
applied by Royo et al129 to the solid phase synthesis of peptides, where they reported 
that the Phacm group had the same stability/lability as Acm, but that Phacm could 
additionally be cleaved by the action of penicillin G acylase. 
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This methodology was therefore attractive to us due to our desire to carry the 
cysteine protected peptide through to the final stage of purification, before 
deblocking the thiol functional groups under mild conditions. Previous work in this 
laboratory had identified several problems in the application of this 
phenyacetylamide protecting group when used to selectively protect the N£ side 
chain of lysine (64)130. It was found that the insolubility of peptides containing this 
phenylacetylamide group caused problems both in purification and final enzyme 
mediated cleavage. Modification of the protecting group (64) by introduction of a 
para hydroxyl group (65) was shown to impart greater solubility to the protected 
peptide and also resulted in a substrate which was hydrolysed at a faster rate by the 
enzyme. Therefore it was also desireable to include this feature in any subsequent 
enzyme cleavable protecting group for cysteine, based on the Phacm group. 
(CH2)4 
"iv NHCHCO ̂ A 
(64) X=H 
(65) X=OH 
3.3.3.1 Synthesis and evaluation of an enzyme cleavable cysteine protecting 
group for use in solid phase peptide synthesis. 
Incorporation of the cysteine derivative (66) during the assembly phase of automated 
SPPS requires that the phenolic hydroxy group is blocked by a protecting group (R') 
which should ideally be removed during TFA cleavage of the peptide from the resin 








However, the synthesis of such a protected cysteine derivative generally involves 
reaction of a cysteine thiol (67) with the stabilised cation (68) under acidic 









Hence, any protecting group for the phenolic oxygen of (66) must therefore be 
sufficiently acid stable to survive the conditions required for formation of (68) but, 
ultimately must be removable at a later stage after incorporation into the polypeptide. 
Kiso et aí131 utilised the 0-methyltyrosine derivative (69) as an acid stable phenol 
protected amino acid during the synthesis of an enkephalin analogue. Removal of the 
methyl ether protecting group at the completion of synthesis was then accomplished 
using a thioanisole -trifluoromethanesulphonic acid (TFMSA) system, via a "push - 
pull" mechanism (Scheme 21). 
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It was therefore decided to synthesise the 4- methoxyphenylacetamidomethyl (4- 
McOPhacm) protected cysteine derivative (66) with the expectation of incorporating 
the protected amino acid (66) into the assembly phase of SPPS which, on cleavage 
from the resin with TFA would yield the polypeptide containing 4- McOPhacm 
protected cysteine residues. The methyl ether could then be removed using the 
method of Kiso131 to give the corresponding 4- hydroxyphenylacetamidomethyl (4- 
OHPhacm) cysteine protected peptide, which was the desired target molecule to 
allow investigation of the enzyme mediated deprotection of the 4- OHPhacm 
protected cysteine residues. 
The Fmoc Na protected 4- methoxyphenylacetamidomethyl cysteine derivative (70) 
was obtained as outlined in Scheme 22 in an overall yield of 37 %. The 
corresponding phenylacetamidomethyl protected cysteine derivative (71) as 
described by Royo et aí129, was also prepared to allow a direct comparison of the 
properties of (70) and (71) once incorporated into polypeptides, and on subsequent 
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Both cysteine derivatives (70) and (71) were then incorporated into a decapeptide 
test sequence, corresponding to the N- terminal residues of salmon calcitonin (SC 1- 
10) (72). Synthesis of the cysteine protected SC 1 -10 was carried out on an ABI 
430A peptide synthesiser, and the products from both syntheses were then cleaved 
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from the resin by treatment with TFA/EDT /water to give the cysteine protected 
peptides (73) and (74). Derivative (75) was then obtained by treatment of (74) with 
Thioanisoletl'FMSA131 followed by gel filtration (Sephadex G -15, 30% AcOH) and 








Each of the SC 1 -10 derivatives (73), (74) and (75) were dissolved/suspended in 
ammonium acetate buffer (0.1M) at pH 8.5 (N.B. both (74) and (75) were soluble, 
but (73) was insoluble), before resin bound penicillin G acylase (kindly supplied by 
SmithKline Beecham Pharmaceuticals Ltd.) was added and the reactions were then 
incubated at 37 °C with gentle agitation. Hplc analysis of each reaction (Figure 21) 
showed that after 24Hrs both (73) and (74) had been consumed to give deprotected 
product, whilst (74) required a further 192Hrs incubation for the enzyme mediated 












Figure 21. Hplc analysis of the reaction of (73) (top) and (75) (bottom) with resin 
bound penicillin G acylase to give the products indicated. 
H.Cys.Ser.Asn.Leu.Ser.Thr.Cy s. Va1.Leu.G1y.OH 
(76) 
The main product of the reaction of (73) with the enzyme was identified as the 
expected cyclic disulphide bridged peptide (76), although a small amount of 
intermolecularly disulphide bridged dimer was also isolated, whilst (75) gave only 
the desired oxidised product (76). Subsequent enzyme mediated cleavage reactions 
carried out under an atmosphere of argon and with the addition of 2- mercaptoethanol 
resulted in the production of the reduced linear product (72). 
It was therefore clear that 4- Mc0Phacm protected cysteine could be incorporated 
into a model system which, after treatment with thioanisole1l'rMSA, yielded the 
71 -..u----_.--- 
corresponding 4- OHPhacm cysteine protected polypeptide. This same model system 
was then successfully deprotected by the action of penicillin G acylase to give either 
the fully reduced or oxidised peptide as required. 
3.3.3.2 Ral synthesis C - Incorporation of 4- methoxyphenylacetamidomethyl 
protected cysteine into a synthetic protein. 
In order to ascertain the usefulness of this 4- McOPhacm protected cysteine 
derivative (70) in the synthesis of cysteine containing proteins, restriction alleviation 
protein (Ral) was resynthesised as described previously, but incorporating the 
cysteine residues as the Fmoc derivative (70). Purification of the 4- McOPhacm 
cysteine protected protein was again accomplished with the aid of the Tbfmoc 
protecting group (51) to give essentially pure cysteine protected Ral protein (Figure 
22). 
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Figure 22. Laser desorption mass spectrum of 4- McOPhacm protected Ral protein 
after Tbfmoc purification with Hplc trace inset. 
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This material was then treated with thioanisole/TFMSA to remove the methyl groups 
from the phenolic oxygen of the 4- McOPhacm cysteine protection and desalted by 
gel filtration to give the 4- OHPhacm protected protein. The 4- hydroxy derivative, 
which eluted earlier than the corresponding 4- methoxyphenyacetamidomethyl 
protected protein on Hplc, was then incubated with immobilised penicillin G acylase 
in an attempt to generate the deprotected Ral protein. 
Initial attemps to remove the cysteine protection using the immobilised enzyme 
supplied by SKB, resulted in complete absorption of the protein onto the solid 
support used to immobilise the enzyme. This absorption was subsequently shown to 
be due to the fact that the solid support was based on an ion exchange material which 
very quickly bound any free basic protein present in solution49. Therefore a second 
immobilised enzyme was obtained, which utilised a polymeric solid support, and the 
removal of the cysteine protecting groups was attempted once more. Hplc 
monitoring (Figure 23) indicated that after 24 hours incubation at 37 °C three main 
peaks were produced. 
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Figure 23. Hplc of 4- OHPhacm protected Ral after treatment with Penicillin G 
acylase, with inset of MALDITOF mass spectrum obtained from each isolated peak. 
30 
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Each of these peaks was isolated and analysed by mass spectrometry. This revealed 
that each peak, although resolvable by Hplc, actually contained a mixture of 
incompletely deprotected species (Cys protected Ral protein requires MH+ =8258, 
Ral requires MH+ =7605) which gave essentially identical mass spectra (Figure 23). 
The presence of free thiol groups in each separate peak was confirmed by Ellman 
assay112. Further attempts to deprotect the cysteine residues completely by adding 
soluble enzyme gave no improvement in Hplc profile, although analysis of the 
reaction products by isoelectric focussing gel electrophoresis did indicate that the 
initially basic protein (pI 8.5) was losing basic residues to give a more acidic protein. 
This result can only be explained if the rate of the forward reaction (Scheme 19), to 
produce the free thiol and phenylacetic acid, is sufficiently slowed down due to steric 
interactions between the synthetic protein and the enzyme, to allow the reverse 
reaction (Scheme 23), between phenylacetic acid and an amine group to 
predominate. This reverse reaction, which is normally negligible at pH 8.5 and 37 °C, 
would result in amide bond formation between lysine side chains and the liberated 
phenylacetic acid, thus resulting in production of a more acidic protein of similar 
molecular weight to the initial 4- OHPhacm cysteine protected Ral. 
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Scheme 23. 
CH2CO2H 
In an attempt to overcome this shift in the equilibrium, a search of the literature 
revealed that Wang et a1132 had also encountered difficulties in the deprotection of 
N- phenylacetylated insulin using immobilised penicillin G acylase. They attributed 
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the incomplete deprotection of the protected insulin derivative to the fact that the 
size of the substrate would result in a lower collision frequency with the active site 
of the enzyme compared to that of the liberated phenylacetic acid and hence the 
equilibrium (Scheme 23) would shift to favour the reverse reaction. However, they 
were successful in overcoming the reversibility of the enzyme mediated deprotection 
reaction by adding a column of strong basic ion exchange resin to the experimental 
apparatus used to perform the enzyme reaction. This successfully sequestered the 
liberated phenylacetic acid which resulted in isolation of fully deprotected insulin. 
Attempts to reproduce the reported reaction conditions132 with 4- OHPhacm protected 
Ral protein resulted in almost complete absorption of protein onto the ion exchanger, 
and no measureable removal of enzyme cleavable cysteine protection. Subsequent 
attempts at varying the reaction conditions by altering the ionic strength and 
temperature of the enzyme reaction failed to give any further improvement and at 
this point the enzyme work was abandoned. 
Recently the crystal structure of penicillin G acylase has been reported133 and the 
publication of its three dimensional structure goes some way to explaining the 
difficulties encountered in its use as a reagent for protecting group removal. Figure 
24 shows the three dimentional crystal structure of the enzyme, in which the B chain 
N- terminal serine, single amino acid catalytic centre, is just discernable at the apex 
of the 13- strand buried deep in the centre of the molecule. Clearly the relative 
inaccessibility of the active site means that, whilst small unstructured molecules are 
allowed access to the binding pocket and are rapidly deacetylated, larger protein 
molecules (which will adopt some degree of structure under the reaction conditions) 
will have a lower collision frequency with the active site of the enzyme. This could 
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result in either incomplete deprotection or a shift in the equilibrium (Scheme 23) to 
favour the reverse reaction, which in turn could lead to enzyme catalysed acylation 
of free amino groups during deprotection of cysteine protected proteins. 
Figure 24. MOLSCRIPT representation of the three- dimenfional crystal sructure of 
penicillin acylase (top) Blue =A chain, Red =B chain showing ball and stick active 
site serine side chain (B1) and (bottom) an orthogonal view, coloured as described 
previously133. 
76 
3.3.4 Synthesis D - Trityl protection 
Our desired synthetic strategy utilising the affinity based protecting group 
Tbfmoc73,74 dictated the necessity for semi -permanent thiol protection, due to the 
fact that removal of the Tbfmoc group involved strongly basic conditions which had 
previously been shown to result in the formation of polymeric aggregates in the 
presence of free thiol groups134,135. The necessity for such strongly basic conditions 
(pH13) was called into question by the observed instability of Tbfmoc protected 
amino acid derivatives in weakly basic solvents such as DMF135. Indeed, earlier 
work by Irving135 had previously suggested that the removal of the Tbfmoc group 
could be accomplished in aqueous solution, at pH values where any thiol groups 
present could be maintained in the reduced state by the addition of Clelland's reagent 
(DTT)136. Although use of such mildly basic conditions would preclude the affinity 
purification of Tbfmoc labelled polypeptides on porous graphitised carbon (PGC), 
due to the slower rate of deprotection with weak base on the solid phase74 compared 
to that observed in solution. 
(77) 
In order to test this proposed methodology for the synthesis of cysteine containing 
proteins, Ral protein was again synthesised with the cysteine residues being 
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incorporated as the ñ phenylmethyl (trityl) derivative (77)137. The assembly was 
carried out on a 0.25mM scale using an ABI 430A peptide synthesiser and at the 
completion of the assembly phase, the Tbfmoc group (51) was introduced to the free 
N- terminus of the resin bound Ral by treatment with chloroformate (52) and DIEA 
with sonication. The resin bound Tbfmoc labelled Ral protein was then thoroughly 
washed with dichloromethane and dried to give 2.2g of resin bound product. 
Cleavage of 0.5g of the resin bound product (TFA/EDT /thioanisole /phenol/TIS 
/water), followed by rapid evaporation of TFA and precipitation with diethyl ether 
gave the crude Tbfmoc- protein, which was applied to the top of a column of 
Sephadex G -50 and eluted with aqueous acetic acid. 
The Tbfmoc- protein containing samples were then pooled and purified by Hplc, 
monitoring at 364nm to isolate only the Tbfmoc labelled protein, which was 
subsequently lyophilised to yield 140mg of solid. Removal of the Tbfmoc group 
under reducing conditions was accomplished by dissolving the solid material 
(140mg) in 6M guanidine.HC1 (0.1M TRIS, pH 8.5) containing a large excess of 
dithiothreitol (Clellands reagent, DTT). This solution was then incubated at 37 °C 
and monitored by Hplc (Figure 25). 
) 
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Figure 25. Hplc monitoring of Tbfmoc deprotection in 6M Gdm.HC1 at pH 8.5 
under reducing conditions to give crude fully reduced Ral protein (solid line). 
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After 3 hours incubation the deprotection of Tbfmoc was judged to have gone to 
completion and the fully reduced Ral protein was isolated after desalting (Sephadex 
G -50, 30% AcOH) and Hplc to give 40mg of pure protein (Figure 26). Ellman 
assay112 for free thiols gave a value of 3.7 thiols /molecule which compares well with 
the expected value of 4 thiols /molecule. This material was then fully characterised 
by mass spectrometry and amino acid analysis. 
Spectroscopic studies on the synthetic fully reduced Ral protein failed to show any 
binding of cobalt ions, and NMR spectra run in the presence and absence of Zn2+ 
ions indicated that the protein was not undergoing any structural change due to metal 
ion binding. 
3.3.4.1 Folding of synthetic Ral 
Since Ral showed no structural features in the reduced state when in the presence of 
metal ions, it was decided to investigate if oxidative folding to give a disulphide 
bridged structure would result in any secondary structure formation. The fully 
reduced protein was therefore folded using the method of Jaenicke and Rudolph136. 
Hplc monitoring of the folding reaction showed no change in elution profile, 
although isolation of the single peak material after folding for 24 hours and assay for 
free thiol groups using the method of Ellman112 confirmed that there were no free 
thiols present in the protein. 
Although the folded Ral protein appeared homogeneous by Hplc (Figure 26), the 
presence of differently disulphide bridged isomers was not precluded. Mapping of 
the disulphides was therefore carried out by digesting the folded Ral with trypsin and 











Figure 27. Laser desorption mass spectrum of major fragments produced on tryptic 
digestion of folded Ral protein. 
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The results of the disulphide mapping are summarised in Table 3, and indicate the 
presence of a single disulphide bridged folded form. The identification and location 
of the disulphide pairings between the four cysteine residues in Ral was deduced 
from the signals at m/z 3206.6, 3327.5, 4123.8 and 4661.4 (Figure 27 and Table 3) 
which establish the Cl 1-C26 disulphide arrangement. The disulphide between C17- 
C20 was not observed, due to the fact that the fragment containing this disulphide 
(CNGCK M.Wt= 524.4) was obscured by matrix associated signals in the spectum. 
However, the abscence of peaks due to the other possible disulphide bridged 
fragments (C11-C17, C11-C20, C17-C26 and C20 -C26) gives added support for the 
presence of a single isomer. 
Peak label 
Predicted 
Fragment* Calc. MH+ Found MH+ % Error 
A 22 - 41 2327.0 2316.4 -0.5 
B 8 - 29 2592.0 2628.7 +1.4 
C 1 - 15- S -S -17 -29 3207.9 3206.6 0.0 
D 8 - 15- S -S -22 - 41 3335.5 3327.5 -0.2 
E 1 - 29 3383.0 3386.9 +0.1 
F 1 - 15- 5-5-22 - 41 4123.9 4123.8 0.0 
G F + Fe ** 4179.8 4179.5 0.0 
H 1 - 15- S -S -22 - 45 4631.1 4661.4 +0.6 
Table 3. *Predicted fragments are numbered according to the sequence given in 
Figure 10. S -S denotes fragments linked by a disulphide bridge. * *Residual iron 
from the mass spectrometer sample plate. 
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3.3.4.2 Comparison of synthetic and recombinant Ral. 
At this point in time, a new batch of recombinant Ral became available117 and was 
compared against the folded synthetic material obtained from synthesis D. Previous 
attempts to overexpress the protein resulted in production of a truncated sequence 
(section 3.3.2.1). However, the new batch of recombinant protein co- eluted with the 
folded synthetic Ral protein when co- injected on Hplc (Figure 28), and when 
analysed by mass spectrometry gave a molecular ion corresponding to the expected 
Ral sequence minus the N- terminal methionine. N- terminal sequencing confirmed 
that there was no N- terminal methionine present in the recombinant protein, 
although the protein did contain the expected sequence of amino acids117. 
Mapping of the disulphides, by mass spectroscopy of the protein after partial tryptic 
digest, also confirmed that the same fragments (minus the N- terminal Met) were 
generated from the recombinant protein, as were found in the folded synthetic Ral 
(Figure 29). Therefore it was unambiguously established that, with the exception of 
the post -translational removal of methionine, the recombinant and synthetic proteins 
were identical in structure and contained the same disulphide pairings. 
Disappointingly, neither material has exhibited any of the biological activity 
attributed to the ral gene product94, when assayed for by monitoring the effect of 





Figure 28. Hplc co- injection of synthetic and recombinant Ral. 
30 
Figure 29. Comparison of the fragments obtained by MALDITOF on partial tryptic 
digest of synthetic (top) and recombinant (bottom) Ral protein. 
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3.3.4.3 CD and NMR studies on synthetic Ral 
The circular dichroism (CD) spectra obtained from synthetic folded Ral protein are 
illustrated in Figure 30(a). In aqueous solution the oxidised protein shows no a- 
helical structure and 46% (3 -sheet with the remainder of the protein being random 
coil. However, a- helical structure could be induced by changing the dielectric 
constant of the solvent as described previously (Section 2.2.4.1). 
Nuclear magnetic resonance spectra acquired from a sample of the folded synthetic 
Ral protein show very little dispersion of backbone amide protons (Figure 30(b)), 
which is characteristic of an unstructured random coil. Similar spectra were obtained 
for the fully reduced protein in the presence of zinc ions, thus further supporting the 
argument that Ral does not contain a motif capable of forming a zinc finger. 
ß00001L0.0 
Wavelength (na) 
- AB208 (OX) 0.4114/a1 0.02ca 20/10/94 COFiiOPr 











9.0 8.0 7.0 
D1 (ppm) 
Figure 30. (a) CD spectra obtained from folded synthetic Ral. 
(b) Part of the 2D NOESY spectrum obtained from a sample of folded synthetic Ral 
protein, indicating the lack of dispersion on NH signals consistent with a random coil 
structure 
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CHAPTER FOUR : MONOCYTE CHEMOTACTIC PROTEIN (MCP -1) 
4.1 General 
Our approach towards the synthesis of Ral protein has allowed us to study the most 
effective route to obtaining a pure, completely deprotected cysteine containing 
protein, which can then be folded into a single conformation. Our studies suggest 
that incorporation of cysteine residues as the triphenylmethyl (trityl) protected 
derivative (77) results in unambiguous removal of the thiol protection, which seems 
to be an important factor during oxidative folding of the reduced protein. As a test of 
the generality of this approach we then chose to synthesise a cysteine containing 
protein, that could then be compared against native or recombinant protein of known 
biological activity, in order to assess the success of our synthetic methodology in 
producing a fully active folded protein. We therefore chose to attempt the total 
chemical synthesis of one of the chemokine family of proteins, namely MCP -1. 
Chemokines are proinflammatory cytokines that attract and activate specific types of 
leukocytes138. Chemokines can be grouped into two subfamilies, a and 13, based on 
differences in both their primary structure and chromosomal location. In chemokine- 
a proteins, a single amino acid separates the two cysteine residues nearest the N- 
terminus and hence they are often referred to as C -X -C proteins. Whilst in the case 
of the ß- chemokines the two cysteines nearest the amino terminus are adjacent to 
each other and are referred to as C -C proteins. 
Monocyte chemoattractant protein -1 (MCP -1) is a member of the (3- chemokine 
family of cytokines and the amino acid sequence of this 76 amino acid protein139 is 






Figure 31. Amino acid sequence of MCP -1 
In contrast to a- chemokines such as IL -8, which attract and activate neutrophils, ß- 
chemokines tend to attract and activate monocytes. MCP -1 has been shown to be 
active in vitro at sub -nanomolar concentrations14o and has also been detected in a 
variety of pathological conditions. 
Crystal141 and solution142 structures for IL -8 have been solved and indicate that IL -8 
is active as a homodimer. Much less is known about the structures of ß- chemokines 
such as MCP -1, although modelling143 and gel -filtration results144 have predicted the 
existence of MCP -1 as a dimer. Further evidence that 13-chemokines exist as dimers 
has recently been supported by the publication of the solution structure of the ß- 
chemokine hMIP -1(3 (human macrophage inflammatory protein - 113) by Lodi et 
a1145. The three dimensional structure of this member of the 13- subfamily of 
chemokines shows that hMIP -1 ß exists as a symmetrical homodimer under the 
experimental conditions of the structural investigations. However, whilst the hMIP- 
113 monomer is similar in structure to that of IL -8, the quarternary structures of the 
hMIP -1 ß and IL -8 dimers are entirely different and hence the previously reported 
modelled structure of MCP -1143 is incorrect. 
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4.2 Chemical synthesis of MCP -1 
The chemical synthesis of the a- chemokine IL -8 has previously been reported'°°, 
although to our knowledge no 13- chemokine has ever been successfully assembled 
and purified. Thus when we were approached by Dr. Rodney Kelly (MRC 
Reproductive Biology Unit, Edinburgh) and asked to chemically synthesise MCP -1, 
it seemed the ideal test of our synthetic methodology for the production of cysteine 
containing proteins. 
Assembly of the MCP -1 sequence (Figure 31) was initially carried out on a 
0.086mM scale as described in the experimental section. However, in our initial 
synthesis, monitoring of coupling efficiency by UV69 indicated that Asn6 had failed 
to couple to the resin bound MCP -17 -76 and hence the amino terminus was 
subsequently acetylated under automated control of the synthesis. This meant that 
the protein could not be purified using our Tbfmoc strategy. However, upon 
cleavage of the protein from the resin and gel filtration of the crude material, Hplc 
analysis of the resulting fractions (Figure 32) indicated that there was sufficient of 
the expected Ac- MCP -17-76 present to allow purification by conventional methods 
in order to study the folding and biological activity of this analogue. 
Figure 32. Hplc of crude Ac- MCP -17 -76 after gel filtration. 
87 
The protein containing fractions were pooled and lyophilised to give 55mg of crude 
acetylated MCP - 17-76. The protein was then folded as described previously136, 
during which Hplc monitoring indicated the earlier elution of the folded, disulphide 
bridged protein. After 24 hours the folding solution was acidified (AcOH) and 
loaded onto a semi- preparative Hplc column. Elution with a linear gradient of 
acetonitrile (0.1% TFA) gave a single main peak which was collected and 
lyophilised to yield 50mg of pure Ac- MCP -17 -76 (Figure 33), which was fully 
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In addition to this, a sample of the pure folded Ac- MCP -17 -76 was subjected to 
partial digestion by trypsin, and the fragments generated were then analysed by mass 
spectrometry. The fragments obtained (Figure 34 and Table 4) give support for the 
presence of only the expected C11 -C36 and C12 -052 disulphide bridged species, due 
to the fact that no fragment from the possible unnatural mixed disulphide pairing of 
C36 -052 was observed. 
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Figure 34. Mass spectrum of the fragments obtained from Ac -MCP -1 




Fragment* Calc. MH+ Found MH+ % Error 
A 59 - 69 1373.6 1376.3 +0.2 
B Ac -7 - 19 1431.6 1431.4 0.0 
C B- S -S -36 - 38 1774.8 1777.0 +0.1 
D B- S -S -50 - 56 2203.0 2203.8 0.0 
E B- S -S -31 - 38 2293.0 2307.2 +0.6 
F 
Ac- 7- 18 -S -S- 
(36 -38 + 50 -56) 2549.2 2548.8 0.0 
G 
Ac- 7- 19 -S -S- 
(36 -38 + 50 -56) 2677.3 2677.7 0.0 
H Ac- 7- 38020 -24 3151.0 3153.2 0.0 
Table 4. *Predicted fragments are numbered according to the sequence given in 
Figure 31. S -S denotes fragments linked by a disulphide bridge, whilst fragments in 
brackets indicate the presence of more than one disulphide bridge from the 
preceeding fragment. 
4.3 Comparison of synthetic Ac- MCP -1746 with recombinant MCP -1 
The synthetic, slightly shortened MCP -1 derivative (Ac- MCP - 17-76) has been 
shown to behave in several test systems as though it is largely the correct 
sequence146. When investigated by radioimmunoassay, after radioiodination on 
tyrosine146, the synthetic material binds in a comparable way to the recombinant 
protein. In addition, comparison of the synthetic analogue and recombinant protein 
by western blot analysis146 shows that the synthetic material (Figure 35, lane 4) runs 
as a dimer of _ 14KDa. This dimer is also slightly lower in molecular weight when 
compared to the recombinant protein dimer (Figure 35, lane 5) as would be expected 
for the truncated sequence. 
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Figure 35. Western blott showing Ac -MCP -1 (lane 4) and 
recombinant MCP -1 (lane 5). 
4.4 Second chemical synthesis of MCP -1 
Although the results from the truncated MCP -1 derivative (Ac -MCP- 17 -76) were 
encouraging, previous work by Zhang et al147 had confirmed that MCP -1, like IL -8, 
requires the N- terminal amino acid sequence for full biological activity. We 
therefore resynthesised the desired sequence (Figure 31) using optimised coupling 
cycles over the areas of the assembly where data from the previous synthesis had 
indicated slow coupling. At the completion of the assembly phase, the N- terminal 
Fmoc group was replaced by Tbfmoc and the pure Tbfmoc -MCP -1 was subsequently 
isolated, after cleavage (TFA/EDT /thioanisole /water/TIS /phenol) and size exclusion 
chromatography (Sephadex G -50, 30 %AcOH), by semi- preparative Hplc 
(monitoring at 364nm). The solid Tbfmoc- MCP -1, obtained after lyophilisation, was 
then deprotected under reducing conditions (6M Gdm.HC1, 0.1M TRIS pH 8.5, 
DTT, 37 °C) for four hours, before being desalted (Sephadex G -50, 30 %AcOH) and 
lyophilised. The crude reduced protein (Hplc Figure 36) was then folded by stirring 
for three days in 1M guanidine.HC1 (0.1M TRIS, pH 8.5, 250m1) containing 1mM 
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EDTA, 0.3mM oxidised and 3mM reduced glutathione. As observed for the 
truncated Ac- MCP- 17 -76, the oxidised folded MCP -1 eluted earlier than the reduced 


























25.I 00 30.00 35.00 40 00 
0.00 5100 10.00 15100 20.00 25.00 30100 35.00 
Figure 36. Hplc traces (top) of the crude reduced MCP -1 (dashed line) overlayed 
with the crude folded protein (solid line) and (bottom) the pure folded MCP -1. 
The folding solution was then acidified (AcOH) and loaded onto a semi -preparative 
Hplc column, before being eluted with a linear gradient of acetonitrile (0.1 %TFA). 
The pure folded MCP -1 (Hplc Figure 36) was collected and lyophilised, before being 
characterised by mass spectrometry and amino acid analysis. Thus, cleavage of 0.5g 
Tbfmoc labelled resin bound MCP -1 yielded 4mg of purified folded protein. In 
addition to this mapping of the disulphides, by mass spectrometry of the fragments 
obtained on partial tryptic digest (Figure 37 and table 5), again confirmed that only 
92 
the expected C 1 1-C36 and C12-052 fragments were observed. Further support for 
the presence of only the correctly folded disulphide bridged MCP -1 is given by the 
lack of any fragments due to the unnatural C36 -052 mixed disulphide. 
Peak Label 
Predicted 
Fragment* Calc.MH+ Found MH+ % Error 
A 59 - 69 1373.6 1375.8 +0.2 
B 57 - 69 1629.8 1648.6 +1.2 
C 1 - 19 2156.5 2142.5 -0.6 
D 1- 19- S- S -31 -38 3020.5 3099.9 +2.6 
E 
1 - 18 -S -S- 
(36 -38 + 56) 3151.6 3155.3 +0.1 
Table 5. *Predicted fragments are numbered according to the sequence given in 
Figure 31. S -S denotes fragments linked by a disulphide bridge, whilst fragments in 
brackets indicate the presence of more than one disulphide bridge from the 
preceeding fragment. 
Figure 37. Mass spectrum of the fragments obtained from MCP -1 
on partial tryptic digest 
This chemically synthesised MCP -1 is currently undergoing testing for biological 
activity146 in comparison with the recombinant protein. 
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CHAPTER FIVE : CONCLUSIONS AND RECOMMENDATIONS 
The preceding chapters have covered the chemical synthesis and purification of 
proteins of biological interest. Use of our strategy for the chemical synthesis and 
purification of proteins which do not contain cysteine or disulphide bridges, such as 
MBD (Section 2.2), has been shown to result in the rapid isolation of homogeneous 
protein in high yield. Tbfmoc73,74 based purification of this type of molecule can be 
accomplished either by affinity binding the Tbfmoc labelled protein to PGC75, or by 
utilising the hydrophobicity and specific absorbance of the Tbfmoc group (max 
364nm) to aid Hplc purification. However, the choice of thiol protection for the 
synthesis of cysteine containing proteins remains an unresolved problem. Although 
penicillin G acylase cleavable cysteine protection can be successfully applied to short 
peptide sequences, initial studies indicate that this type of protecting group strategy 
will not be generally applicable to the production of chemically synthesised proteins. 
At the present time our studies indicate that the synthesis of molecules such as Ral 
(Section 3) and MCP -1 (Section 4), are best approached by incorporating the 
cysteine residues as the triphenylmethyl (trityl) protected derivative (77), and ideally 
using only trityl/t -Bu based protection for the remaining residues. 
The protein should subsectntly be purified, after labelling with Tbfmoc, cleavage 
from the solid support and size exclusion chromatography, by isolating the pure 
Tbfmoc labelled protein by reverse phase Hplc (monitoring at 364nm). The Tbfmoc 
group should then be removed under mildly basic reducing conditions, which 
preserve the protein in the reduced state, before allowing the protein to fold and 
purifying to homogeneity. A generalised scheme for the purification of cysteine 
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CHAPTER SIX : BIOLOGICAL AMIDATION OF PEPTIDES 
6.1 General 
One of the most prevalent post -translational modifications of peptide hormones is C- 
terminal amidation, with approximately 50% of all known peptide hormones being 
C- terminally amidated148. This amide functionality is required for full biological 
activity, the corresponding carboxylic acid being much less active, and also act as a 
protection against degradation by C- terminal exopeptidases. 
Most peptide amides are biosynthesised from larger precursor proteins which are 
then processed to peptides extended by an extra glycine residue at the C- terminus. 
Bradbury et aí149 were the first to show that the conversion of this glycine extended 
peptide to the corresponding peptide amide was catalysed by an enzyme, now 
commonly referred to as peptidy/glycine a- amidating enzyme (a -AE, EC 1.14.17.3), 
which they had extracted from porcine pituitary. It has subsequently been shown that 
similar enzymes are present in many tissue sources and it has been suggested that 
these are a family of closely related proteins, with a similar substrate requirement, 
which generate a host of amidated hormones150. 
Recent work by Katopodis151 and others152 has shown that instead of a 
monofunctional enzyme being responsible for the conversion of glycine extended 
peptides to peptide amides, there is in fact a two step mechanism in operation which 
utilises a bifunctional enzyme (derived from a single structural gene), which can 
either catalyse the full amidation reaction or may be cleaved into two 
monofunctional protein domains which can then act separately153. These two 
monofunctional enzymes are referred to as peptidyl -a- hydroxyglycine 
monooxygenase (PHM, EC 1.4.17.3) and peptidylamidoglycolate lyase (PAL, EC 
4.3.2.5). 
96 
The overall mechanism of amidation153 (Scheme 25) has been shown to involve 
PHM catalysed removal of the pro -S hydrogen from the C- terminal glycine residue 
(78) and simultaneous addition of a hydroxyl group, with retention of configuration, 
to give an S- a- hydroxyglycine residue (79) in a process dependant on oxygen, 
copper and ascorbate. The second enzyme, PAL, then catalyses the decomposition of 
the a- hydroxyglycine extended intermediate (79) to the amide (80) and glyoxylic 
acid. This second step occurs spontaneously at alkaline pH154, but under 
physiological conditions requires the action of the PAL enzyme and has been shown 
to be stereospecific153'155. 
O Hs HR O OH HR O ,\ 
RN CO2H P RNCO2H PAL RN'H 
H OZ, Cu, H H 
Ascorbate 
(78) (79) (80) 
Scheme 25. 
Because many peptide amides play an important role in the regulation and activation 
of biochemical processes, the discoverey that the amidation of these molecules 
proceeds via an a- hydroxyglycine extended intermediate raises the question as to 
whether these intermediates have a biological function or, indeed, could be used as a 
basis for control of in vivo hormone production. 
6.2 Synthesis of a- hydroxyglycine extended peptides. 
Previous reports of synthetic a- hydroxyglycine extended peptides have relied on the 
condensation of short peptide amides with glyoxylic acid at elevated temperatures, as 
described by Young and TamburinP55 (Scheme 26) for the synthesis of N- dansyl- 
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Scheme 26. i) Glyoxylic acid monohydrate ii) TFA 
The synthesis of a- hydroxyglycine extended peptides has also been described more 
recently by the reaction of recombinant PHM enzyme on synthetic glycine extended 
peptides, to produce a- hydroxyglycine extended human calcitonin156 and a- 
hydroxyglycine extended human growth hormone releasing factor157. 
We sought to find a general route to a- hydroxyglycine extended peptides by 
introducing the a- hydroxyglycine residue (81), or some protected derivative of (81) 
as the C- terminal residue in the assembly phase of Fmoc based SPPS. It was hoped 
that this would then allow the synthesis of peptide sequences of varying length and 
complexity. 
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The synthesis of Na- 9- fluorenylmethoxycarbonyl -a- hydroxyglycine (83) was 
achieved by a variation of the method reported by Ben -Ishai and Zoller158 for the 
synthesis of the corresponding Z protected derivative (82). Fmoc carbamate was 
treated with glyoxylic acid (5 eq.) in gently refluxing ethyl acetate for 6 hours to 
give racemic (83) as a white powder in 73% yield (Scheme 27). Attempts to protect 
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the secondary alcohol in (83) as the corresponding t -Bu, MEM or THP ethers failed 
to yield any of the desired products, although dehydration of (83) with concentrated 
sulphuric acid in methanol159 yielded the a- methoxyglycine methyl ester derivative 
(84) by addition of methanol to the intermediate iminium anion formed on acid 




















Treatment of (84) with lithium hydroxide in aqueous acetone allowed hydrolysis of 
the methyl ester to give the free carboxylic acid (85) on work up as a white powder 
in 68% overall yield from (83) (Scheme 27). This method of ester hydrolysis gave 
only low levels of Fmoc deprotection as monitored by t.l.c. and is an attractive 
alternative to the use of orthogonal carboxylic acid protection for the synthesis of 
Fmoc derivatives. 
The a- methoxyglycine derivative (85) was then immobilised for use in SPPS by 
esterification of the free carboxylic acid with resin bound 4- benzyloxybenzyl alcohol 
(Wang resin12). Optimum conditions required overnight sonication of an excess of 
(85), DMAP, HOBt and DIC with the Wang resin in DMF. This gave a 61% yield of 
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Resin (86) was then employed for the synthesis of gastrin derivative (87). The 
synthesis was carried out on a 0.486mM scale on an ABI 430A peptide synthesiser. 
Fmoc deprotection monitoring during the synthesis indicated only a 60% 
incorporation of phenylalanine. This was expected as Kawai et a1159 had previously 
reported that the methyl ester of a- methoxyglycine was unstable, could not be 
isolated, and could only be incorporated into a dipeptide by generation in situ from 
the corresponding Z derivative in the presence of a mixed anhydride of Boc - 
phenylalanine (Scheme 29). 
O OCH3 
Boc-Phe-OCO2Bu' 
O N CO H Boc-Phe-DL-GIy(OMe)-OMe 
H 
2 H2/Pd -15°C 
Scheme 29 
A more worrying aspect was that the incorporation of aspartic acid was only 34.6% 
of the initial substitution. This drop in coupling at the dipeptide stage is 
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characteristic of diketopiperazine (DKP) formation. This well known side reaction in 
peptide synthesis16° involves a base catalysed cyclisation of the dipeptide to form a 
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Scheme 30 
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The remaining residues were successfully incorporated without further decrease in 
coupling efficiency, and the desired diastereomeric pentapeptides were isolated in 
low yield after cleavage (TFA/EDT /water) and semi- preparative Hplc. The 
diastereomers, due to the R and S configuration of the racemic a- hydroxyglycine 
residue, were separable by Hplc and gave identical mass spectra and amino acid 
analysis. Transformation of the C- terminal a- methoxyglycine to a- hydroxyglycine 
is thought to proceed via the corresponding imine intermediate, which is generated 
on acidolysis. This imine is then thought to be hydrolysed to the a- hydroxyglycine 
extended peptide on aqueous work up. 
Whilst the initial synthesis confirmed that this was a viable route to the desired a- 
hydroxyglycine extended peptides, the problem of DKP formation resulted in a low 
yield of the desired compound. Several solutions to the problem of DKP formation 
during solid phase synthesis have been reported, the most elegant and generally 
applicable of which involves the use of 2- chlorotrityl chloride functionalised resin 
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(10)14,161. This resin is reported to completely suppress DKP formation162 by 
exploiting the relatively large volume of the trityl group to sterically block any 
cyclisation. We therefore employed this resin for the synthesis of gastrin derivative 
(88) and cholecystokinin (CCK) derivative (89). In both cases deprotection 
monitoring confirmed that no DKP formation had occured during synthesis, and both 
compounds were obtained in good yield after cleavage from the resin 
(TFA/EDT /water) and semi -preparative Hplc. 
H. Glu. Glu .Ala.Tyr.Gly.Trp.Met. Asp .Phe. a- (OH)G1y.OH 
(88) 
H.Asp .Tyr.Met.Gly .Trp.Met.Asp.Phe. a- (OH)Gly.OH 
(89) 
The diastereomeric prides (88) and (89) were inseparable by Hplc (Figure 38), 
although the presence of two diastereomers was confirmed by NMR. The ratio of the 
diasteromers was found to be 1:1 in (88) and 0.8:1 in (89), as determined by 
integration of the signal due to the aH of the a- hydroxyglycine residue in each of 











Figure 38. Hplc traces of crude and purified (88) (top) and (89) (bottom). 
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AIM 1. MO at 315 - 1N II! 5..clrv .l 5111111. 
1.1 5.1 5.1 5.4 5.8 L'S 4.8 4.8 4.4 4'8 pp. 
1, 1,1 i1 1 111 r-1--r- 
5.2 5.0 4.8 4.6 4.4 4.2 4.0 3.8 3.6 ppm 
Figure 39. NMR spectra showing the all signal (arrowed) due to the racemic a- 
hydroxyglycine residue in (88) (top) and (89) (bottom). 
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In conclusion, we have shown that it is possible to introduce a- methoxyglycine as 
the C- terminal residue in the assembly phase of Fmoc SPPS. Subsequent acid 
treatment and aqueous work up not only causes side chain deprotection and cleavage 
of the peptide from the resin, but also converts the C- terminal residue to a- 
hydroxyglycine. The biological function of these a- hydroxyglycine extended 
peptides with respect to C- terminal amidation is currently under investigation. 
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CHAPTER SEVEN : EXPERIMENTAL 
7.1 Notes 
All amino acids were purchased from either Bachem, Novabiochem, Raylo or were 
synthesised as described in the text, and are of the L- configuration unless otherwise 
stated. Melting points were determined using a Koffler hot stage melting point 
apparatus and are uncorrected. Optical rotations were measured on an AA 1000 
polarimeter (Optical Activity Ltd.) using a 10.0cm cell in the solvent indicated in the 
text. Analytical thin layer chromatography (t.l.c.) was carried out using a 0.3mm 
layer of silica (Merck, kieselgel 609) containing 0.5% woelm fluorescent indicator, 
on foil plates in the solvents indicated in the text. The components were observed 
under ultra -violet light, by reaction with iodine vapour and by charing of the plate 
after spraying with 20% sulphuric acid in methanol. Infrared specta were recorded 
on either a Perkin -Elmer 781 or Bio -RAD SPC 3200 instrument. Ultra- violet spectra 
were recorded on a Varian Cary 210 spectrophotometer in the solvents indicated in 
the text. High and low resolution fast atom bombardment (FAB) spectra were 
measured on a Kratos MS5OTC instrument, using either thioglycerol, 3- nitrobenzyl 
alcohol or glycerol as matrix. Routine laser desorption time of flight mass spectra 
were measured on a PerSeptive Biosystems LaserTec Benchtop II system. Circular 
dichroism (CD) spectra were recorded on a JASCO J600 spectropolarimeter 
(University of Stirling). Nuclear magnetic resonance (NMR) spectra were recorded 
on either a Jeol FX -60 (60MHz), a Brucker WP -80 (80MHz), a Brucker WP -200 
(200MHz), a Brucker AC -250 (250MHz), a Brucker WH -360 (360MHz) or a Varian 
VXR5000 (600MHz) instrument in the solvents stated. Elemental analyses were 
performed on a Perkin -Elmer 2400CHN elemental analyzer. Amino acid analysis 
was performed on an LKB 4150 alpha amino acid analyser on the hydrolysate 
obtained after heating samples at 110 °C for 24 hours in a sealed Carius tube, 
followed by evaporation to dryness. Peptide sequencing was carried out on an 
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Applied Biosystems 477A sequencer at the Welmet sequencing facility, University 
of Edinburgh. Polyacrylamide molecular weight gels were run using 20% 
homogenious SDS gels (Pharmacia) on an LKB Pharmacia PhastGel electrophoresis 
system, and developed using coomassie blue staining. 
All solvents were distilled before use and the following were dried using the reagents 
given in parenthesis when required : dichloromethane (calcium hydride), diethyl 
ether (sodium wire), tetrahydrofuran (sodium,benzophenone). Peptide synthesis 
grade dimethylformamide (DMF), 1,4- dioxan and piperidine were obtained from 
Rathburn Chemicals, Walkerburn Scotland. Peptide synthesis grade trifluoroacetic 
acid was obtained from Applied Biosystems (ABI). High performance liquid 
chromatography (Hplc) was carried out using either an ABI system, comprising 2X 
1406A solvent delivery systems, an 1480A injector /mixer and an 1783A 
detector /controller, or a Gilson system, comprising 2X 306 solvent delivery systems, 
an 811C dynamic mixer, an 805 manometric module, a 119 UV/VIS detector and 
Gilson 715 software- driven gradient controller. Components were eluted from 
various columns, as described in the text, by a linear gradient of acetonitrile (far UV 
grade, Rathburn Chemicals) in Milli -Q grade water, where both solvents contained 
0.1% v/v of Hplc grade trifluoroacetic acid (Fisons). 
7.2 Solid phase peptide synthesis 
The polypeptides described were synthesised on an Applied biosy stems 430A 
automated peptide synthesiser fitted with a UV monitoring system as described 
previously69. All peptides were synthesised using the 9- fluorenylmethoxycarbonyl 
(Fmoc) strategy of Na protection. This involves the complementary use of 
orthogonal acid labile side chain protection and an acid labile peptide -resin linker. 
The side chain protecting groups used were as follows : t -butyl (But) ethers for 
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serine, threonine and tyrosine; t -Bu esters for aspartic and glutamic acid; t- 
butoxycarbonyl (Boc) for lysine; t-triphenylmethyl (trityl) for histidine; 2,2,5,7,8 - 
pentamethylchroman-6- sulphonyl (Pmc) for arginine. The carboxamide side chains 
of asparagine and glutamine were incorporated as either the 4,4'- 
dimethoxybenzhydryl (MBH) or trityl derivatives, or without side chain protection 
as indicated in the text. Cysteine was incorporated as either the t- butylsulphenyl 
(StBu), acetamidomethyl (Acm), phenylacetamidomethyl (Phacm), 4- 
methoxyphenylacetamidomethyl (4- McOPhacm) or trityl derivatives as indicated in 
the text. TbfmocC174 was prepared using the method of Irving75. 
7.2.1 Coupling of the C- terminal amino acid onto 4- alkoxybenzylalcohol 
(Wang) resin. 
A solution of Fmoc amino acid (1mM) and N,N- diisopropylcarbodiimide (DIC) 
(0.5mM) in DMF (20m1) was stirred for 15 minutes at room temperature, then 4- 
benzyloxybenzylalcohol functionalised polystyrene resin (Wang) (1.0g, 0.8mM) was 
added, together with a catalytic amount of 4- (N,N'- dimethylamino)- pyridine and the 
mixture was then sonicated for 1 -2 hours. The functionalised resin was then removed 
by filtration and sequentially washed with DMF, 1,4 -dioxan and dichloromeAhane, 
before being dried under vacuum. The loading of the functionalised resin was then 
determined by treating a known weight of resin with 20% piperidine/DMF in a 10m1 
volumetric flask, for 20 minutes in a sonic bath. The UV absorbance of the 
supernatant was then measured at 302nm and the loading calculated using the Beer - 
Lambert law (£302 = 15400 for fulvene -piperidine adduct). This procedure generally 
gives a resin with a functionality in the region of 0. I mM/g. To obtain higher resin 
loadings (0.5- 0.6mM/g), the amounts of Fmoc amino acid and DIC were increased to 
5.0mM and 2.5mM respectively. 
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7.2.2 Automated SPPS 
Synthetic proceedures were pre -programmed into the ABI 430A synthesiser prior to 
the comencement of synthesis. Routinely most residues were incorporated using 
double couple cycles, in which the first coupling cycle utilised a preformed 
symmetrical anhydride, followed by the second coupling using a preformed 1- 
hydroxybenzotriazole (HOBt) ester. The exceptions to this were the amino acids 
asparagine, glutamine and histidine, which were coupled twice via their HOBt esters 
and glycine, which was coupled singly as a symmetrical anhydride. 
Each synthetic cycle involved (1) a capping step to block any unreacted amino 
groups. (2) Deprotection of the base labile Fmoc group. (3) Coupling of the next Na 
protected amino acid. Each of these steps was followed by thorough washing of the 
resin and each cycle was then repeated with the chosen amino acid in order to build 
up the desired sequence of amino acids in a stepwise manner from the C- terminus to 
the N- terminus. The preprogrammed synthetic cycles are summarised below. 
1. Capping - The resin was vortexed with a solution of acetic anhydride (0.5M), 
DIEA (0.125M) and HOBt (0.2% w /v) in DMF (10m1) for 10 minutes, before the 
capping solution was drained from the vessel and the resin washed by six portions of 
DMF. 
2. Deprotection - The resin was vortexed with a solution of 20% piperidine/DMF for 
3 minutes before being drained. An aliquot of the deprotection solution was then sent 
to a UV detector in order to quantify the amount of fulvene -piperidine adduct 
present and hence subsequently gave an indication of the percentage incorporation of 
each residue. Deprotection was then repeated for a second time for 1 minute in order 
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to establish if the Na protecting group had been completely removed. Finally the 
resin was washed with six portions of DMF /1,4- dioxan (1;1). 
3. Coupling - The resin was vortexed with a solution of 0.5mM Fmoc amino acid 
preformed symmetrical anhydride (formed from 1mM Fmoc AA and 0.5mM DIC in 
the activator vessel). The first coupling cycle was allowed to continue for 30 minutes 
before the solution was drained from the reaction vessel and the resin washed with 
two portions of DMF. The resin was then vortexed for a second 30 minute period 
with 0.5mM of Fmoc amino acid HOBt active ester (preformed from 0.5mM Fmoc 
AA, 0.5mM HOBt and 0.5mM DIC) before being drained and washed with four 
portions of DMF. For certain difficult couplings the coupling cycle time was 
extended or alternatively a third coupling of HOBt ester was incuded as required. 
7.3 Experimental 
Methylated DNA Binding Domain of MeCP2 (MBD) (MeCP2 78 -162) 
The synthesis was carried out on an initial scale of 0.144mM using the functionalised 
resin Fmoc Arg(PMC)- (OCH2C6H4OR) (1.0192g, 0.142mM/g). All amino acid side 
chains were protected as described previously with the exception of asparagine and 
glutamine, which were incorporated without side chain protection. All amino acids 
(with the exception of glycine) were double coupled, apart from residues 69 to 56 
which were treble coupled with the third coupling cycle time extended, and residues 
41 to 25 which were allowed to couple for an extended period during the second 
coupling cycle. The N- terminal Fmoc group was left on at the completion of the 
assembly phase and the resin bound product was capped for 30 minutes in a sonic 
bath before being washed sequentially with DMF, 1,4- dioxan, dichloromethane and 
dried to give 2.8178g of resin bound product. 
500mg of the Fmoc protected, resin bound product was treated with 20% 
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piperidine/DMF (10m1s) for 10 minutes in a sonic bath, before the resin bound 
product was filtered off, washed with DMF, 1,4- dioxan, dichloromethane and dried. 
This dry resin was then added to a suspension of TbfmocCl (52) (230mg, 0.5mM) in 
dichloromethane (10m1) and DIEA (64µL, 0.37mM) was added before the reaction 
flask was sealed, covered in aluminium foil and sonicated for three hours with 
occasional mixing. The resin bound Tbfmoc- protein was then washed thoroughly 
with dichloromethane, dried (functionality by UV75 = 0.04mM/g) and cleaved from 
the resin by stirring for 4 hours in the dark, with a mixture of TFA (10m1), Phenol 
(0.75g), EDT (1.5m1), thioanisole (0.5m1) and water (0.5m1). The resin was then 
removed by filtration and the filtrate concentrated in vacuo to give an oil, which 
yielded solid Tbfmoc- protein on trituration with diethyl ether. The solid Tbfmoc- 
protein was then filtered off, washed with diethyl ether and dissolved in aqueous 
acetic acid (50 %) before being applied to the top of a column of Sephadex G -50 (10 
x 800mm) and eluted with aqueous acetic acid (30 %). Pure Tbfmoc- protein was 
obtained by semi- preparative Hplc (Vydac C18, 250 x 22mm, 1011M, A =H2O, 
B= CH3CN, 0.1% TFA; 9m1/min. 10 -70% B over 40 min.364nm) and 
concentrated to a small volume (5 -10m1) by lyophilisation. The Tbfmoc was then 
deprotected by adding piperidine (1ml) and mixing for 5 minutes, before the solution 
was cooled on ice, acidified (AcOH), applied to the top of a column of Sephadex G- 
50 (10 x 800mm)and eluted with aqueous acetic acid (30 %). The protein containing 
fractions were then pooled and pure MBD protein was obtained after semi - 
preparitive Hplc (Vydac C18, 250 x 22mm, 10µM, A =H2O, B= CH3CN, 0.1% TFA; 
9m1/min. 10 -70% B over 40 min.214nm) and lyophilisation as a white solid 
(32.8mg); amino acid analysis (48Hr. hydrolysis): Asx,0 9.53, Thr5 4.44, Ser7 5.80, 
Glx6 7.09, Pro6 5.83, Gly7 7.27, Ala4 4.43, Val4 4.00, Met, 1.05, Ile4 3.87, Leu5 
5.26, Tyr4 4.12, Phe4 4.09, Lys8 8.08, Arg9 9.16, Trp, (N /A); m/z (laser desorption) 
9727, C431H683N1260129S1 requires 9726.0; Hplc (Vydac C18, 250 x 4.6mm, 5µM, 
A =H2O, B= CH3CN, 0.1% TFA; lml/min. 10 -70% B over 45 min.214nm), Rt= 
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24.0 min., 42.5 %B. In addition, the first twenty six amino acid residues were 
sequenced by Edman degradation and were found to be in agreement with the 
required sequence. 
Oligodeoxyribonucleotide Synthesis and Purification 
Synthetic DNA sequences (53) and (54) were obtained from OSWEL, University of 
Edinburgh, and purified using the method of Ramage and Wahl87ab. DNA 
concentrations, after Hplc and Sephadex G -25 purification, were determined at 
260nm and ambient temperature in aqueous solution. 
Duplex formation was acheived by mixing equimolar amounts of each 
oligonucleotide strand, this solution was subsequently heated at 70 °C for 5minutes 
and then allowed to cool very gradually to room temperature. 
Bandshift Assay 
Protein -DNA binding reactions were carried out in 20mM MES (pH6.3), 1mM 
EDTA, 3mM MgC12, 10 mM mercaptoethanol, 10% glycerol, 0.1% TRITON X -100 
and 60mM NaCl. Increasing amounts of protein were incubated with the DNA on ice 
for 30 minutes, then loaded onto a 5% polyacrylamide gel and run for 4 hours. at 
100v and 4 °C. After 4 hours the gel was placed onto cling -film and then onto a t.l.c. 
plate which allowed visualisation of the bands by exposure to UV light (254nm). 
Restriction Alleviation Protein - Synthesis A 
The synthesis was carried out on a 0.2mM scale using the functionalised resin Fmoc 
Ala- (OCH2C6H4OR). All amino acid side chains were protected as described 
previously, with the exception of asparagine and glutamine which were incorporated 
as the corresponding 4,4'- dimethoxybenzhydryl (MBH) derivatives, and cysteine 
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which was incorporated as the t- butylthio (StBu) derivative. All residues (with the 
exception of glycine) were treble coupled and at the completion of the assembly the 
resin bound material was washed sequentially with DMF, 1,4- dioxan, 
dichloromethane and dried. 
Cleavage of the protein from the resin with simultaneous deprotection of all side 
chain protecting groups, with the exception of Cys -StBu, was accomplished by 
stirring the 250mg of the dry resin bound protein with a mixture of TFA (30m1), 
EDT (0.75m1), water (1.5m1) amd phenol (2.25g) for 5 hours under an atmosphere of 
dry nitrogen. The protein was then isolated by evaporation of the TFA under reduced 
pressure and trituration with diethyl ether. The crude cleaved protein was applied to 
a column of Sephadex G -50 (10 x 800mm), eluted with aqueous acetic acid (30 %) 
and the desired fractions were then pooled and lyophilised to give 40mg of solid 
protein. This material was then dissolved in 95 %TF'E /5% water (10m1) and to this 
stirring solution was added an excess of tributylphosphine (0.1m1). Hplc monitoring 
(Aquapore C8, 200 x 4.6mm, 7µM; A =H2O, B= CH3CN, 0.1% TFA, lml/min. 10- 
90 %B over 25 minutes, X=214nm) showed complete disappearance of starting 
material (Rt= 14.2min., 57 %B) and appearance of a less hydrophobic product 
(Rt= 12.8min., 53 %B) after 5 hours. The reduced protein was isolated by evaporation 
to a small volume (0.5m1) and trituration with diethyl ether. The product was 
isolated by filtration, dissolved in aqueous acetic acid (30 %) and lyophilised to give 
29mg of white solid; amino acid analysis: Asx7 6.2, Thr5 3.5, Ser, 1.0, Glx9 10.5, 
Prot 3.0, Gly4 3.9, Alas 5.3, Cys4 2.4, Val3 3.2, Met5 3.8, Ilea 2.5, Leu2 2.0, Tyr, 1.2, 
Phe2 2.0, Lys8 7.5, Arg3 2.5, Trp2 N /A. 
This material proved extremely insoluble in a variety of buffers, and attempts to 
further purify this synthetic protein proved unsuccessful. Polyacrylamide gel 
electrophoresis showed a broad smear which was indicative of the presence of 
multiple products of similar size. This was probably due to incomplete coupling 
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and/or capping during assembly and resulted in an accumulation of similar deletion 
sequences which co- purified with the desired sequence. 
Restriction Alleviation Protein - Synthesis B 
The synthesis was carried out on a 0.22mM scale using Fmoc -Alanine functionalised 
2- methoxy -4- alkoxybenzylalcohol (SASRIN) resin (490mg, 0.45mM/g). All amino 
acid side chains were protected as described previously, with the exception of 
asparagine and glutamine which were incorporated as the corresponding 4,4'- 
dimethoxybenzhydryl (MBH) derivatives, and cysteine which was incorporated as 
the acetamidomethyl (Acm) derivative. All amino acids (with the exception of 
glycine) were double coupled, with the first 12 residues being coupled in a glass 
vessel in a sonic bath connected to the ABI 430A peptide synthesiser. The resin 
bound product (Fmoc Ral 66 -55) was then transferred back into a conventional 
reaction vessel and the synthesis continued using standard cycles except for the 
regions 54 -45 and 30 -1 which were allowed to couple for an extended period of 
time. At the end of the synthesis the Fmoc was left on the N- terminal methionine, 
and the resin bound product was capped for 30 minutes in a sonic bath. The resin 
was then washed with DMF, 1,4- dioxan, dichloromethane and dried to give 1.6g of 
Fmoc resin bound protein. 
A 650mg portion of the resin was then treated with 20% piperidine/DMF for 30 
minutes in a sonic bath befor being filtered off, washed with DMF, 1,4- dioxan, 
dichloromethane and dried. The dry resin bound protein was then added to a 
suspension of TbfmocCl (100mg, 0.22mM) in dichloromethane (10m1) and DIEA 
(30111, 0.17mM) was added before the reaction flask was sealed, covered in 
aluminium foil and then sonicated for 5 hours with occasional mixing. The Tbfmoc- 
peptide -resin was then filtered off, washed thoroughly with dichloromethane and 
dried. The dry Tbfmoc resin bound protein (functionality by UV75 = 0.054mM/g) was 
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then added to a mixture of TMSBr (1.32m1), EDT (2m1), thioanisole (1.2m1), m- 
cresol (0.1m1) and TFA (10m1) at 0 °C under an atmosphere of dry nitrogen, and 
allowed to stir at 0 °C for 5 hours whilst protected from daylight. The resin was then 
removed by filtration and the filtrate concentrated in vacuo to give an oil, which 
yielded solid Tbfmoc- protein on trituration with diethyl ether. The solid Tbfmoc- 
protein was then filtered off, washed with diethyl ether and dissolved in aqueous 
acetic acid (50 %) before being applied to the top of a column of Sephadex G -50 (10 
x 800mm)and eluted with aqueous acetic acid (30 %). Pure Tbfmoc- protein was 
obtained by semi- preparative Hplc (Vydac C18, 250 x 22mm, 1011,M, A =H2O, 
B= CH3CN, 0.1% TFA; l0m1/min. 10 -90% B over 30 min. X=364nm) and 
concentrated to a small volume (5 -10m1) by lyophilisation. The Tbfmoc was then 
deprotected by adding piperidine (1m1) and mixing for 5 minutes, before the solution 
was cooled on ice,acidified (AcOH), applied to the top of a column of Sephadex G- 
50 (10 x 800mm)and eluted with aqueous acetic acid (30 %). The protein containing 
fractions were then pooled and pure tetra Acm protected Ral protein was obtained 
after semi -preparitive Hplc (Vydac C18, 250 x 22mm, 141,M, A =H2O, B= CH3CN, 
0.1% TFA; 10m1 /min. 10 -90% B over 30 min. X,-.214nm) and lyophilisation as a 
white solid (19mg); amino acid analysis: Asx7 6.58, Thr5 4.68, Seri 0.99, Glx9 10.37, 
Prot 3.95, Gly4 3.99, Alas 5.00, Cys4 1.88, Val3 3.10, Met5 5.00, Ilea 2.86, Leu2 
2.11, Tyri 0.48, Phe2 2.01, Lys8 7.82, Arg3 2.71, Trp2 (N /A); m/z (laser desorption) 
7885, C338H54197O102S9 requires 7889.34; Hplc (Vydac C18, 250 x 4.6mm, 511,M, 
A =H2O, B= CH3CN, 0.1% TFA; l ml/min. 10 -90% B over 30 min. X=214nm), Rt= 
15.4 min., 59 %B. 
The stable Acm protecting groups on the four cysteine residues were removed by 
dissolving the pure Ral(Acm)4 (35mg) in water (20m1) and adjusting the pH to 4.0 
with ammonium hydroxide (2M). Mercury (II) acetate (100mg) was then added and 
the mixture was allowed to stir overnight at room temperature. This solution was 
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then lyophilised, before the protein was fully reduced and denatured by dissolving 
the residue in 6M Gdm.HC1 (50mM TRIS pH8.0) containing 20% v/v 
mercaptoethanol and stirring overnight. This solution was then applied to a column 
of Sephadex G -50 (10 x 800mm) and eluted with aqueous acetic acid (30 %). Further 
purification of the protein containing fractions by Hplc (Aquapore C18, 250 x 
10mm, 10µM, A =H2O, B= CH3CN, 0.1% TFA; 5m1/min. 0 -50% B over 30 min. 
X=214nm) gave 10mg white solid after lyophilisation; amino acid analysis: Asx7 
7.04, Thr5 4.74, Seri 1.32, Glx9 10.70, Prot 2.44, Gly4 4.05, Alas 4.77, Cys4 2.43, 
Val3 3.11, Met5 4.42, Ilea 3.13, Leu2 2.06, Tyri 1.14, Phe2 2.11, Lys8 7.87, Arg3 
3.33, Trp2 (N /A); m/z (laser desorption) 7669*, C326H526N93O98S9 requires 7604.94; 
Hplc (Aquapore C18, 220 x 4.6mm, 7µM, A =H2O, B= CH3CN, 0.1% TFA; 
lml/min. 10 -50% B over 30 min. X=214nm), Rt= 26.2 min., 45 %B. The first 22 
amino acid residues were sequenced by Edman degradation and found to be in 
agreement with the required sequence. *Ellman assay for free thiols112 gave a value 
of one thiol per molecule (requires 4), and although initially this was thought to be 
due either to rapid oxidation of the reduced protein, recent evidence from high 
resolution mass spectra suggests that the cysteine residues were incompletely 
deprotected (see Section 3.3.2.1). 
N- Hydroxymethyl- 4- methoxyphenylacetamide 
This compound was prepared by the general method of Ben -Ishai et a1163. A mixture 
of 4- methoxyphenylacetamide (5.38g, 0.032M), aqueous formaldehyde (40% w /v, 
12.5m1) and aqueous sodium hydrogen carbonate (5% w /v, 7.5m1) were heated on a 
boiling water bath until a clear solution was obtained (_10 min.). The reaction 
mixture was cooled for one hour and then extracted with ethyl acetate (3 x 25m1). 
The organic layer was dried (MgSO4), filtered and evaporated to give a white solid 
which was triturated with diethyl ether, filtered off and dried to yield 4.89g (78.3 %) 
of the title compound as a white powder; m.p.117- 118 °C; (found: 
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C,61.39;H,6.90;N,7.13, C10H13NO3 requires: C,61.52; H,6.71; N,7.18°Io);t.l.c. 
(CHC13/MeOH/AcOH, 85:10:5) Rf 0.55, (CH3CN/CHC13/AcOH, 8:1:1) Rf 0.6; 
vmax(KBr disc) 3320 (amide NH), 3254 (OH), 1655 (C=0), 1612, 1543, 1511 cm' 
(aromatic); Xnlax(MeOH) 277nm (E 17800 dm3mol-1cm 1), 284nm (16000); 
5H[(CD3)2S0, 200MHz] 8.60 (1H, Br t, NH); 7.21-6.82 (4H, q, aromatics); 5.59 
(1H, t, J=6.81Hz, OH); 4.50 (2H,t, J=6.60Hz, NHCH2OH);3.71 (3H, s, OCH3); 3.35 
(2H, s, CH2); 5C[(CD3)2S0, 50MHz] 130.26 (aromatic CH); 128.21 (aromatic 
quarternary); 113.78 (aromatic CH); 62.61 (NHCH2OH); 55.15 (OCH3); 41.84 
(CH2); m/z (FAB) 196 (MH+), HRMS found 196.09737, C10H14NO3 requires 
196.09736 therefore <lppm. 
S-( 4- Methoxyphenylacetamidomethyl ) -L- cysteine 
TFA (12m1) was added to a stirring suspension of L- cysteine (free base) (0.9g, 
7.4mM) in dichloromethane (60m1) at 0 °C, and a suspension of N-hydroxymethyl-4- 
methoxyphenylacetamide (1.46g, 7.5mM) in dichloromethane (50m1) was then 
added portionwise over a 10 minute period. The reaction mixture was then 
evaporated and the residue chased with diethyl ether to give a white solid. This solid 
was then isolated by filtration, washed with water, EtOH and dried to give 1.46g of 
the title compound as a white powder; m.p.200 °C (dec.); (found: 
C,52.51;H,6.18;N,9.59, C13H18N2O4S requires: C, 52.33; H,6.08; N,9.39%); [a]D24 = 
-49.1 °(c =1 in TFA); t.l.c. (n- BuOH/pyridine /AcOH/water, 15:10:3:2) Rf 0.6; 
umax( r disc) 3440 (OH), 3200 (NH), 1639 (C =0), 1613, 1542, 1513 cm-1 
(aromatic); 5H[CF3CO2D /(CD3)2SO, 200MHz] 8.39 (1H, Br s, NH); 6.89 (4H, AB 
q, J =8Hz, aromatics); 4.35 (1H, d, J= 13.5Hz, aCH); 4.11 (2H,t, J =14Hz, NHCH2S); 
3.59 (3H, s, OCH3); 3.36 (2H, s, CH2); 3.0 (2H, m, ßCH2); 6C[CF3CO2D /(CD3)2SO, 
50MHz] 175.02 (acid C =0); 171.59 (amide C =0); 160.67 (aromatic quarternary); 
132.22 (aromatic CH); 129.19 (aromatic quarternary); 115.85 (aromatic CH); 56.40 
(OCH3); 54.39 (aCH); 43.35,42.98 (CH2);32.33 (13CH2); m/z (FAB) 299 (MH +), 
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HRMS found 299.10657, C13H19N2O4S requires 299.10654 therefore <lppm. 
Ná(9-Fluorenylmethoxycarbony1)-S-(4'-methoxyphenylacetamidomethyl)-L- 
cysteine (70) 
4- Methoxyphenylacetamidomethyl -L- cysteine (0.69g, 2.31mM) was suspended in a 
mixture of 1,4- dioxan/water (1:1, 50m1) and the pH adjusted to between 8 and 9 with 
solid sodium carbonate. A solution of FmocOSu (0.56g, 1.67mM) in acetonitrile 
(25m1) was then added and allowed to stir overnight. The volume was then reduced 
by evaporation under reduced pressure, and then the pH was adjusted to 3 with 2M 
HC1. Extraction with ethyl acetate, washing with water, drying (MgSO4) and 
evaporation yielded a white solid which, after trituration with hot ethyl acetate and 
cooling was isolated by filtration. The solid was then washed with ethyl acetate, 
diethyl ether, and dried to give 0.62g (71% based on FmocOSu) of the title 
compound as a white powder; m.p.152- 154 °C; (found: C,64.71;H,5.58;N,5.50, 
C28H28N2O6S requires: C,64.60;H,5.42;N,5.38 %); [a]D24 = -32.8 °(c =1 in DMF); 
t.l.c. (CHC13/MeOH/AcOH, 90:8:2) Rf 0.20, (CHC13/MeOH/AcOH, 85:10:5) Rf 0.6; 
vmax(KBr disc) 3358 (OH), 3316 (NH), 3064 (aromatic CH), 2927 (aliphatic CH), 
1697 (C =0), 1616 cm-1 (aromatic); 2max(Me0H) 266nm (E 26000dm3mol-1 cm 1), 
290nm (6800), 300nm (7800); ÖH[(CD3)2S0, 200MHz] 12.80 (1H, Br s CO2H); 
8.69 (1H, Br s, NH); 7.9 -7.28 (9H, m, Fmoc aromatics + NH); 7.19 (4H, AB q, 
J =8Hz, aromatics); 4.27 (6H, Br m, Fmoc CH2CH +aCH +SCH2N); 3.71 (3H, s, 
OCH3); 3.39 (2H, s, CH2); 2.94 (2H, m, ßCH2); 8C[(CD3)2SO, 50MHz] 172.56 (acid 
C =0); 170.92 (amide C =0); 158.08 (aromatic quarternary); 156.22 (urethane C =0); 
143.95, 140.89 (aromatic quarternary); 130.16 (aromatic CH); 128.06 (aromatic 
quarternary); 127.83, 127.26, 125.47, 120.29, 113.82 (aromatic CH); 65.95 (Fmoc 
CH2); 55.13 (OCH3); 54.23 (aCH); 46.77 (Fmoc CH); 41.56, 40.61 (CH2);31.84 
(ßCH2); m/z (FAB) 521 (MH +), HRMS found 521.17464, C28H29N2O6S requires 
521.17462 therefore <lppm. 
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Ná( 9- Fluorenylmethoxycarbonyl)- S-( phenylacetamidomethyl )- L- cysteine (71) 
This compound was prepared using the general method of Albericio et al129,164. To a 
suspension of N- hydroxymethylphenylacetamide165 (6.9g, 42mM) and cysteine.HCl 
monohydrate (7.33g, 42mM) in water (15m1) under argon at 0 °C was added a 
mixture of TFMSA/TFA (1:19, 50m1). After stirring at 0 °C for 90 minutes the 
reaction mixture was evaporated and repeatedly chased with diethyl ether (5 x 50m1) 
to give an oil which was used immediately for the next step. 
The above oil was suspended in water /1,4- dioxan (1:1, 500m1) and the pH adjusted 
to 9 -10 with solid sodium carbonate. FmocOSu (11.33g, 33.6mM) in acetonitrile 
(100m1) was then added and the reaction was allowed to stir overnight before being 
poured into water (1000m1), acidified to pH 2 (2M HC1) and extracted with ethyl 
acetate. The organic layer was then washed with brine, dried (MgSO4) and 
evaporated to give a white solid. Trituration with diethyl ether and drying under 
vacuum gave the title compound 14.17g (86% based on FmocOSu) as a white 
powder; m.p. 156 -158 °C; (found: C,66.64;H,5.97;N,5.71, C27H26N2O5S requires: 
C,66.10;H,5.34;N,5.78 %); [a]D24 = -35.2 °(c =1 in DMF); t.l.c.(CHC13/MeOH/AcOH, 
90:10:5) Rf 0.54; vmax(KBr disc) 3370 (OH), 3000 -2900 (CH), 1716 (urethane 
C =0), 1685 (acid C =0), 1626cm 1 (aromatic); ?ax(MeOH) 266nm (E 
24500dm3mol-1cm 1), 290nm (5800), 300nm (7600); 8H[(CD3)2SO, 200MHz] 
13.00 (1H, Br s CO2H); 8.77 (1H, t, J= 6.16Hz, NH); 7.9 -7.19 (14H, m, aromatics + 
NH); 4.37 -4.21 (6H, Br m, Fmoc CH2CH +aCH +SCII2N); 3.48 (2H, s, CH2); 3.03 
(2H, m, 3CH2); 8C[(CD3)2S0, 50MHz] 172.54 (acid C =0); 170.57 (amide C =0); 
156.22 (urethane C =0); 143.95, 140.89 ,136.18 (aromatic quarternary); 129.16, 
128.40, 127.83, 127.26, 126.56, 125.47, 120.28 (aromatic CH); 65.95 (Fmoc CH2); 
54.22 (aCH); 46.78 (Fmoc CH); 42.44, 40.62 (CH2); 31.86 (ßCH2); m/z (FAB) 492 
(MH +), HRMS found 491.16408, C27H27N2O5S requires 491.16405 therefore 
<lppm. 
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Salmon Calcitonin 1 -10 (CSNLSTCVLG) 
The above sequence was synthesised twice on a 0.25mM scale using the 
functionalised resin Fmoc- Gly- (OCH2C6H4OR). All amino acid side chains were 
protected as described previously with the exception of cysteine. In synthesis A the 
cysteine residues were incorporated as the phenylacetamidomethyl derivative (71), 
and in synthesis B as the 4- methoxyphenylacetamidomethyl derivative (70). All 
residues were double coupled, and at the completion of the assembly phase the resin 
bound product was washed sequentially with DMF, 1,4- dioxan, dichloromethane and 
dried. 
Synthesis A 
Cleavage of the peptide from the resin and simultaneous removal of all side chain 
protecting groups, with the exception of the acid stable phenylacetamidomethyl 
cysteine protection, was accomplished by stirring 650mg of the resin bound peptide 
with a mixture of EDT (2m1) and TFA/water (95:5, 10m1) for 3 hours at room 
temperature. Evaporation of the TFA and precipitation with diethyl ether gave the 
bis- phenylacetamidomethyl cysteine protected peptide (73) as a white solid (80mg); 
Hplc (Vydac C18, 250 x 4.6mm, 51,1,M, A =H2O, B= CH3CN, 0.1% TFA; lml/min. 
10 -90% B over 30 min. k=214nm), Rt= 16.4 min., 54 %B; m/z (FAB) 1330 (MK +), 
1315 (MNa +),1291 (MH +), HRMS found 1290.58699, C57H88N13O17S2 requires 
1290.58626 therefore < +/- 1ppm. 
Synthesis B 
Cleavage of the peptide from the resin and simultaneous removal of all side chain 
protecting groups, with the exception of the acid stable 4- 
methoxyphenylacetamidomethyl cysteine protection, was accomplished by stirring 
1g of the resin bound peptide with a mixture of EDT (2m1) and TFA/water (95:5, 
10m1) for 3 hours at room temperature. Evaporation of the TFA and precipitation 
with diethyl ether gave the bis- phenylacetamidomethyl cysteine protected peptide 
(74) as a white solid (150mg); Hplc (Vydac C18, 250 x 4.6mm, 5µM, A =H2O, 
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B= CH3CN, 0.1% TFA; lml/min. 10 -90% B over 30 min. X=214nm), Rt= 19.8 min., 
63.5 %B; m/z (FAB) 1372 (MNa +), 1350 (Mt), HRMS found 1350.61782, 
C59H91N13O19S2 requires 1350.60739 therefore < +/- l0ppm. 
Conversion of the 4- methoxyphenylacetamidomethyl cysteine protected peptide (74) 
to the 4- hydroxyphenylacetamidomethyl protected peptide (75) was carried out 
according to the method of Kiso et aí131. A 30mg portion of the 4- 
methoxyphenylacetamidomethyl cysteine protected peptide (74) was treated with a 
mixture of TFMSA (0.9m1, 10mM), thioanisole (0.6m1, 5mM) and TFA (5m1) for 30 
minutes at 0 °C and then for a further 2 hours at room temperature. Evaporation of 
the TFA and gel filtration (Sephadex G -15, 30% AcOH) to remove TFMSA salts 
gave peptide containing fractions which were further purified by semi- preparative 
Hplc (Vydac C18, 250 x 22mm, 1011M, A =H2O, B= CH3CN, 0.1% TFA; 9m1/min. 
10 -70% B over 30 min. X=214nm) to yield 21mg of 4- 
hydroxyphenylacetamidomethyl cysteine protected peptide (75) on lyophilisation; 
Hplc (Vydac C18, 250 x 4.6mm, 5µM, A =H2O, B= CH3CN, 0.1% TFA; lml/min. 
10 -90% B over 30 min. X=214nm), Rt= 14.8 min., 50 %B; m/z (FAB) 1322 (MH +), 
HRMS found 1322.57690, C57H88N13O19S2 requires 1322.57609 therefore < +/- 
l ppm. 
Enzyme Mediated Deprotection of Cysteine Protected Salmon Calcitonin 1 -10 
As a general method, a 15mg portion each of the bis- cysteine protected peptides 
(73), (74),and (75) was added to ammonium acetate buffer (20m1, 0,1M,pH8.5) and 
the pH re- adjusted to 8.5. Resin bound penicillin acylase (0.5g, 1325mega units/Kg, 
supplied by SmithKline Beecham Pharmaceuticals Ltd.) was added and the reaction 
mixture was allowed to gently mix whilst incubating at 37 °C. The progress of the 
reaction was monitored by Hplc (figure 21, section 3.3.3.1). Substrates (73) and (75) 
were fully deprotected after overnight incubation, whilst s strate (74) required 9 
days incubation for full deprotection. All substrates yielded the expected cyclic 
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disulphide bridged peptide (76) as the major product of the enzyme reaction, 
although only substrate (75), the 4- hydroxyphenylacetamidomethyl protected 
derivative, gave virtually quantitative conversion to (76). 
At the completion of the reaction, the resin bound enzyme was removed by filtration 
and washed with water. The combined filtrate was then lyophilised and gel filtered 
(Sephadex G -15, 30% AcOH) before the desired product (76) was isolated by Hplc. 
Hence 15mg of bis- 4- hydroxymethylphenylacetamidomethyl cysteine protected 
SC1 -10 yielded 4.2mg of purified SC1 -10 (oxidised) after lyophilisation; amino acid 
analysis: Asx1 1.25, Thr1 0.95, Sere 1.68, Gly1 1.02, Cyst 1.89, Vail 1.03, Leu2 1.84; 
m/z (FAB) 1032 (MK +), 1016 (MNa +), 994(M +), HRMS found 994.44320, 
C39H67N11O15S2 requires 994.43378 therefore < +/- l0ppm.; Hplc (Vydac C18, 250 x 
4.6mm, 511M, A =H2O, B= CH3CN, 0.1% TFA; 1 ml/min. 10 -90% B over 30 min. 
X=214nm), Rt= 13.4 min., 47 %B. 
Restriction Alleviation Protein - Synthesis C 
The synthesis was carried out on a 0.153mM scale using Fmoc -Alanine 
functionalised 2- methoxy -4- alkoxybenzylalcohol (SASRIN) resin (340mg, 
0.45mM/g). All amino acid side chains were protected as described previously, with 
the exception of asparagine and glutamine which were incorporated as the 
corresponding triphenylmethyl (trityl) derivatives, and cysteine which was 
incorporated as the 4- methoxyphenylacetamidomethyl (4- McOPhacm) derivative 
(70). All amino acids (with the exception of glycine) were double coupled, with the 
regions 54 -45 and 30 -1 being coupled for an extended period of time during the 
second coupling cycle. At the end of the synthesis the Fmoc was left on the N- 
terminal methionine, and the resin bound product was capped for 30 minutes in a 
sonic bath. The resin was then washed with DMF, 1,4- dioxan, dichloromethane and 
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dried to give 1.28g of Fmoc resin bound protein. 
A 400mg portion of the resin was then treated with 20% piperidine/DMF for 15 
minutes in a sonic bath befor being filtered off, washed with DMF, 1,4- dioxan, 
dichloromethane and dried. The dry resin bound protein was then added to a 
suspension of TbfmocCl (200mg, 0.44mM) in dichloromethane (10m1) and DIEA 
(3O111, 0.17mM) was added before the reaction flask was sealed, covered in 
aluminium foil and then sonicated for 3 hours with occasional mixing. The Tbfmoc- 
peptide -resin was then filtered off, washed thoroughly with dichloromethane and 
dried. The dry Tbfmoc resin bound protein (functionality by UV75 = 0.069mM/g) was 
then added to a mixture of TMSBr (1.32m1), EDT (2m1), thioanisole (1.2m1), m- 
cresol (O.1m1) and TFA (iOm1) at 0 °C under an atmosphere of dry nitrogen, and 
allowed to stir at 0 °C for 5 hours whilst protected from daylight. The resin was then 
removed by filtration and the filtrate concentrated in vacuo to give an oil, which 
yielded solid Tbfmoc- protein on trituration with diethyl ether. The solid Tbfmoc- 
protein was then filtered off, washed with diethyl ether and dissolved in aqueous 
acetic acid (50 %) before being applied to the top of a column of Sephadex G -50 (10 
x 800mm)and eluted with aqueous acetic acid (30 %). Pure Tbfmoc- protein was 
obtained by semi- preparative Hplc (Vydac C18, 250 x 22mm, 101.1M, A =H2O, 
B= CH3CN, 0.1% TFA; 9m1/min. 30 -90% B over 25 min.364nm) and 
concentrated to a small volume (5 -10m1) by lyophilisation. The Tbfmoc was then 
deprotected by adding piperidine (1m1) and mixing for 5 minutes, before the solution 
was cooled on ice,acidified (AcOH), applied to the top of a column of Sephadex G- 
50 (10 x 800mm)and eluted with aqueous acetic acid (30 %). The protein containing 
fractions were then pooled and lyophilised to give 108mg tetra 4- McOPhacm 
protected Ral protein as a white solid; amino acid analysis: Asx7 6.38, Thr5 4.52, 
Seri 1.02, Glx9 11.26, Prot 2.41, Gly4 3.94, Alas 5.50, Cys4 3.29, Val3 3.09, Met5 
4.29, Ilea 3.35, Leu2 2.08, Tyri 0.41, Phe2 2.02, Lys8 7.54, Arg3 2.90, Trp2 (N /A); 
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m/z (laser desorption) 8337.6 (Na adduct), C367H574N970106S9 requires 8313.8; Hplc 
(Vydac C18, 250 x 4.6mm, 511M, A =H2O, B= CH3CN, 0.1% TFA; lml /min. 10- 
90% B over 30 min. X=214nm), Rt= 18.4 min., 58.5 %B. 
Cleavage of the methyl group at the phenolic oxygen of the 4- McOPhacm cysteine 
protecting group was carried out according to the method of Kiso et aí131.. TFMSA 
(0.9m1) was added to an ice cold stirring solution of 4- McOPhacm protected Ral in a 
mixture of TFA/thioanisole (100:6, 10.6m1) under an atmosphere of nitrogen. After 
stirring at 0 °C for 60 minutes the reaction mixture was allowed to warm up to room 
temperature and was stirred for a further 2 hours. The TFA was removed by 
evaporation and the crude 4- hydroxyphenylacetamidomethyl cysteine protected 
protein was precipitated with diethyl ether (250m1) and filtered off to give a 
hygroscopic solid. This solid was then redissolved in 6M Gdm.HC1 (50mM TRIS pH 
8.0) containing DTT (200mg) and stirred for 30 minutes at 37 °C, before being 
applied to a column of Sephadex G -50 (10 x 800mm) and eluted with aqueous acetic 
acid (30 %). The protein containing fractions were then pooled and lyophilised to 
give a white solid; Hplc (Vydac C18, 250 x 4.6mm, 5µM, A =H2O, B= CH3CN, 
0.1% TFA; lml/min. 10 -90% B over 30 min. X=214nm), Rt= 17.0 min., 55 %B. 
The freeze dried 4- hydroxyphenylacetamidomethyl cysteine protected protein was 
dissolved in ammonium acetate buffer (0.1M, 50m1, pH 8.5) and the pH re- adjusted 
to 8.5 (2M ammonium hydroxide). To this solution was then added 2- 
mercaptoethanol (10m1),0.5g of resin bound penicillin acylase (Sigma). The flask 
was then flushed with argon and sealed, before being incubated at 37 °C with gentle 
agitation. After 72 hours an aliquot of soluble enzyme (0.1m1, Sigma) was added and 
incubated for a further 72 hours. The resin bound enzyme was then removed by 
filtration and the filtrate lyophilised to give solid material. This solid was redissolved 
in 6M Gdm.HC1 (0.1M TRIS pH8.5) containing DTT (excess) and incubated at 37 °C 
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for 2hours, before being desalted by gel filtration (Sephadex G -50, 30% AcOH). 
Hplc analysis of the Ral containing fractions showed three main peaks which, on 
isolation by Hplc, gave identical mass specta corresponding to incompletely 
deprotected protein. This suggested that the enzyme reaction had failed to 
completely remove the enzyme cleavable cysteine protection, although further 
treatment of the partially deprotected protein with fresh enzyme gave no 
improvement in Hplc profile. 
Restriction Alleviation Protein - Synthesis D 
The synthesis was carried out on a 0.25mM scale using Fmoc -Alanine functionalised 
4- alkoxybenzylalcohol resin (400mg, 0.614mM/g). All amino acid side chains were 
protected as described previously, with the exception of asparagine, glutamine and 
cysteine which were incorporated as the corresponding triphenylmethyl (trityl) 
derivatives. All amino acids (with the exception of glycine) were double coupled, 
with the regions 54 -45 and 30 -1 being coupled for an extended period of time during 
the second coupling cycle. At the end of the synthesis the Fmoc was left on the N- 
terminal methionine, and the resin bound product was capped for 30 minutes in a 
sonic bath. The resin was then washed witn DMF, 1,4- dioxan, dichloromethane and 
dried to give 2.18g of Fmoc resin bound protein. 
The resin was then treated with 20% piperidine/DMF for 15 minutes in a sonic bath 
befor being filtered off, washed with DMF, 1,4- dioxan, dichloromethane and dried. 
The dry resin bound protein was then added to a suspension of TbfmocCl (400mg, 
0.88mM) in dichloromethane (20m1) and DIEA (601.11, 0.34mM) was added before 
the reaction flask was sealed, covered in aluminium foil and then sonicated for 3 
hours with occasional mixing. The Tbfmoc -peptide -resin was then filtered off, 
washed thoroughly with dichloromethane and dried. 
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A 500mg portion of the dry Tbfmoc resin bound protein was then added to a mixture 
of EDT (2m1), thioanisole (0.5m1), phenol (0.75g), water (0.5m1), TIS (0.5m1) and 
stirred for 15 minutes, before TFA (1 Oml) was added and the mixture stirred for a 
further 4 hours hours whilst protected from daylight. The resin was then removed by 
filtration and the filtrate concentrated in vacuo to give an oil, which yielded solid 
Tbfmoc- protein on trituration with diethyl ether. The solid Tbfmoc- protein was then 
filtered off, washed with diethyl ether and dissolved in aqueous acetic acid (50 %) 
before being applied to the top of a column of Sephadex G -50 (10 x 800mm)and 
eluted with aqueous acetic acid (30 %). Pure Tbfmoc- protein was obtained by semi - 
preparative Hplc (Vydac C18, 250 x 22mm, 1011M, A =H2O, B= CH3CN, 0.1% TFA; 
9m1/min. 30 -90% B over 25 min. X=364nm) and lyophilised to give 140mg white 
solid. The Tbfmoc was then deprotected under reducing conditions (6M Gdm.HC1, 
pH 8.5 TRIS, 0.1M, containing excess DTT) for 4 hours at 37 °C before being 
desalted (Sephadex G -50, 30% AcOH) and purified by Hplc to give 40mg of fully 
reduced Ral protein after lyophilisation; Asx7 5.11, Thr5 4.74, Ser, 1.07, Glx9 8.08, 
Pro2 2.02, Gly4 4.37, Ala5 5.52, Cys4 0.99, Val3 3.17, Met5 4.48, Ile3 3.12, Leu2 
2.31, Tyr, 0.71, Phe2 2.10, Lys8 8.17, Arg3 3.11, Trp2 (N /A); m/z (laser desorption) 
7607.3, C326H526N93O98S9 requires 7604.49; Hplc (Vydac C18, 250 x 4.6mm, 5µM, 
A =H2O, B= CH3CN, 0.1% TFA; lml /min. 10 -90% B over 30 min. X=214nm), Rt= 
17 min., 56 %B. 
Folded oxidised Ral was obtained by dissolving 29mg of fully reduced protein in 1M 
guanidine.HC1 (0.1M, TRIS, pH 8.5, 250m1) containing 0.1mM EDTA, 0.3mM 
reduced and 3mM oxidised glutathione. After stirring for 2 days at room 
temperature, the single product was isolated by Hplc to give 12mg of folded protein 
after lyophilisation; Asx7 4.26, Thr5 3.86, Ser, 1.07, Glx9 8.08, Pro2 1.44, Gly4 4.91, 
Ala5 5.32, Cys4 2.30, Val3 3.42, Met5 4.29, Ilea 3.17, Leu2 2.39, Tyr, 0.80, Phe2 
2.22, Lys8 7.39, Arg3 3.10, Trp2 (N /A); m/z (laser desorption) 7624.1 (Na adduct), 
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C326H522N93O98S9 requires 7600.9; Hplc (Vydac C18, 250 x 4.6mm, 511M, A =H2O, 
B= CH3CN, 0.1% TFA; lml/min. 10 -90% B over 30 min.214nm), Rt= 17 min., 
56 %B. 
MCP -1 (Ac7 -76) 
The synthesis was carried out on a 0.086mM scale using Fmoc- Thr(OtBu) 
functionalised 4- alkoxybenzylalcohol resin (1.06g, 0.081 mM/g). All amino acid side 
chains were protected as described previously, with the exception of asparagine, 
glutamine and cysteine which were incorporated as the corresponding 
triphenylmethyl (trityl) derivatives, and all amino acids were double coupled. 
The resin (1.8g) was then added to a mixture of EDT (2m1), thioanisole (0.5m1), 
phenol (0.75g), water (0.5m1), TIS (0.5m1) and stirred for 15 minutes, before TFA 
(10m1) was added and the mixture stirred for a further 4 hours. The resin was then 
removed by filtration and the filtrate concentrated in vacuo to give an oil, which 
yielded solid protein on trituration with diethyl ether. The solid protein was then 
filtered off, washed with diethyl ether and dissolved in aqueous acetic acid (50 %) 
before being applied to the top of a column of Sephadex G -50 (10 x 800mm)and 
eluted with aqueous acetic acid (30 %). The protein containing fractions were then 
pooled and lyophilised prior to folding. 
Folded oxidised Ac- MCP -17 -76 was obtained by dissolving 55mg of fully reduced 
protein in 1M guanidine.HC1 (0.1M, TRIS, pH 8.5, 250m1) containing 0.1mM 
EDTA, 0.3mM reduced and 3mM oxidised glutathione. After stirring for 3 days at 
room temperature the folding solution was acidified (AcOH) and loaded onto a semi - 
preparative Hplc column (Vydac C18, 250 x 22mm, 1011M). Elution with a linear 
gradient of CH3CN /0.1 %TFA gave pure folded Ac- MCP -17 -76 (50mg) as a white 
solid after lyophilisation; Asx6 5.88, Thr7 6.39, Ser5 4.28, Glx7 8.14, Pro4 3.30, Alas 
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5.00, Cys4 3.81, Val5 4.72, Metl 1.72, Iles 4.79, Leu2 3.35, Tyre 1.34, Phe2 1.96, 
Hiss 1.08,Lys9 9.38, Argo 3.92, Trpl (N /A); m/z (laser desorption) 8088.5, 
C352H572N101O104S5 requires 8086; Hplc (Vydac C18, 250 x 4.6mm, 5µM, A =H2O, 
B= CH3CN, 0.1% TFA; lml/min. 10 -90% B over 30 min. X=214nm), Rt= 16.6 min., 
54 %B. 
MCP -1 
The synthesis was carried out as described above. However, coupling of residues 46- 
39 and 10 -1 was extended. All amino acids were incorporated as described above, 
with the exception of glutamine 1 which was incorporated unprotected. At the 
completion of the assembly the N- terminal Fmoc group was removed automatically 
on the synthesiser and the resin bound product washed with DMF, 1,4- dioxan, 
dichloromethane and dried. The dry resin bound protein was then added to a 
suspension of TbfmocCl (400mg, 0.88mM) in dichloromethane (20m1) and DIEA 
(7O111, 0.4mM) was added before the reaction flask was sealed, covered 
foil and then sonicated for 3 hours with occasional mixing. The Tbfmoc- peptide- 
resin was then filtered off, washed thoroughly with dichloromethane and dried. 
A 500mg portion of the dry Tbfmoc resin bound protein was then added to a mixture 
of EDT (2m1), thioanisole (0.5m1), phenol (0.75g), water (0.5m1), TIS (0.5m1) and 
stirred for 15 minutes, before TFA (10m1) was added and the mixture stirred for a 
further 4 hours hours whilst protected from daylight. The resin was then removed by 
filtration and the filtrate concentrated in vacuo to give an oil, which yielded solid 
Tbfmoc -protein on trituration with diethyl ether. The solid Tbfmoc -protein was then 
filtered off, washed with diethyl ether and dissolved in aqueous acetic acid (50 %) 
before being applied to the top of a column of Sephadex G -50 (10 x 800mm)and 
eluted with aqueous acetic acid (30 %). Pure Tbfmoc -protein was obtained by semi - 
preparative Hplc (Vydac C18, 250 x 22mm, 1011M, A =H2O, B= CH3CN, 0.1% TFA; 
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9m1/min. 30 -90% B over 25 min. X=364nm) and lyophilised. The Tbfmoc was then 
deprotected under reducing conditions (6M Gdm.HCJ, pH 8.5 TRIS, 0.1M, 
containing excess DTT) for 4 hours at 37 °C before being desalted (Sephadex G -50, 
30% AcOH). The protein containing fractions were then pooled and lyophilised prior 
to folding. 
Folded oxidised MCP -1 was obtained by dissolving the fully reduced protein in 1M 
guanidine.HC1 (0.1M, TRIS, pH 8.5, 250m1) containing 0.1mM EDTA, 0.3mM 
reduced and 3mM oxidised glutathione. After stirring for 3 days at room temperature 
the folding solution was acidified (AcOH) and loaded onto a semi- preparative Hplc 
column (Vydac C18, 250 x 22mm, 10µM). Elution with a linear gradient of 
CH3CN /0. i %TFA gave pure folded MCP -1 (4mg) as a white solid after 
lyophilisation; Asx8 7.84, Thr7 6.49, Ser5 4.78,.G1x8 9.90, Pros 4.93, Ala6 6.77, Cys4 
3.44, Val5 4.73, Met1 1.02, Ile6 5.76, Leu2 2.29, Tyre 1.37 , Phe2 2.23, His1 1.06, 
Lys9 8.27, Arg4 4.13, Trp1 (N /A); m/z (laser desorption) 8681.2, C379H614N1090114S5 
requires 8682; Hplc (Vydac C18, 250 x 4.6mm, 5µM, A =H2O, B= CH3CN, 0.1% 
TFA; lm /min. 10 -90% B over 30 min. X=214nm), Rt= 15.8 min., 52.5 %B. 
Disulphide Mapping by Partial Tryptic Digest 
As a general method, the protein of interest (0.5mg) was dissolved in ammonium 
acetate buffer (0.1M, pH 7.5) containing 0.1mg of trypsin. This sample was then 
incubated at 37 °C for 4 -7 hours before the digestion was stopped by adding 6M HC1 
(5p1). The sample was then lyophilised and analysed by laser desorption mass 
spectrometry. 
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Ná- 9- Fluorenylmethoxycarbonyl- a- hydroxyglycine (83) 
9- Fluorenymethylcarbamate166 (1g, 4.2mM) and glyoxylic acid monohydrate (2g, 
0.022M) were gently refluxed in ethyl acetate (100m1) for 6 hours. The reaction 
mixture was then cooled, washed with water (5 x 50m1), dried (MgSO4) and 
evaporated to give a white solid. Recrystallisation from ethyl acetate/hexane gave the 
title compound as a white solid, (1.19g, 91.9 %); m.p. 214 -216.5 °C; (found: 
C,65.3;H,5.06;N,4.53, C17H15NO5 requires: C,65.2;H,4.83;N,4.47 %); t.l.c. 
(CH3CN /CHC13 /AcOH, 8:1:1) Rf 0.22; vmax(KBr disc) 3600 -3100 br (CO2H and 
OH), 3320 (NH), 1730 (acid C =0), 1700cm 1 (urethane C =0); ? ax(MeOH) 
266nm (E 22900dm3mol -lcm 1), 289nm (6000), 300nm (7200); 6H[(CD3)2S0, 
80MHz] 8.0 -7.21 (8H, m, aromatics); 5.28 (1H, d, J= 8.8Hz, aCH); 4.27 (3H, Br s, 
Fmoc CH2CH); 8C[(CD3)2SO, 50MHz] 169.6 (acid C =0); 154.8 (urethane C =0); 
143.10, 140.30 (aromatic quarternary); 126.8, 126.2, 124.4, 119.0 (aromatic CH); 
76.2 (aCH); 65.80 (Fmoc CH2);46.00 (Fmoc CH); m/z (FAB) 314 (MH +), FIRMS 
found 313.09504, C17H15NO5 requires 313.09502 therefore <lppm. 
Ná- 9- Fluorenylmethoxycarbonyl- a- methoxyglycine methyl ester(84) 
To an ice cold solution of Fmoc -a- hydroxyglycine (83) (13.1g, 0.04M) in absolute 
methanol (150m1) was added conc. sulphuric acid (2m1). This solution was then 
allowed to warm up to room temperature and stirring was continued for 2 days. The 
resulting suspension was then poured into ice cold sodium hydrogen carbonate 
(saturated, 200m1) and extracted with ethyl acetate (100m1). The organic layer was 
then washed with water, dried (Mg504) and evaporated to give a white solid. 
Recrystallisation from ethanol gave the title compound as a white solid (11.6g, 
82 %); m.p. 123 -125.5 °C; (found: C,66.55;H,5.49;N,4.08, C19H19NO5 requires: 
C,66.84;H,5.61;N,4.10 %); t.l.c. (ethyl acetate/hexane, 1:1) Rf 0.44; vmax(nujol) 
3290 (NH), 1760 (ester CO), = 1700cm 1 (urethane C =0); lax(MeOH) 266nm (E 
22000dm3mol-lcm l), 290nm (5600), 300nm (6800); 5H[CDC13, 200MHz] 7.78- 
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7.25 (8H, m, aromatics); 5.97 (1H,d, J=9.54Hz, NH);5.36 (1H, d, J=9.48Hz, aCH); 
4.55-4.38 (2H, m, Fmoc CH2); 4.23 (1H, t,J=6.70Hz, Fmoc CH); 3.80 (3H, s, ester 
OMe); 3.43 (3H, s, ether OMe); 5C[CDC13, 50MHz] 167.83 (ester C=0); 155.54 
(urethane C=0); 143.39, 143.26, 141.07 (aromatic quarternary); 127.56,126.87, 
124.74, 119.80 (aromatic CH); 80.37 (aCH); 66.99 (Fmoc CH2); 55.96 (ether OMe); 
52.69 (ester OMe); 46.79 (Fmoc CH); m/z (FAB) 342 (MH+), HRMS found 
342.13416, C19H20N05 requires 342.13414 therefore <lppm. 
N2- 9- Fluorenylmethoxycarbonyl- a- methoxyglycine (85) 
A solution of LiOH.H2O (0.615g, 0.015M) in water (20m1) was slowly added to a 
stirring ice sold solution of Fmoc -a- methoxyglycine methyl ester (84) (5g, 0.015M) 
in acetone /water (4:1, 400m1). The resulting suspension was then stirred for a further 
30 minutes before evaporating to a small volume (_80m1) to remove most of the 
acetone. Extraction with ethyl acetate (200m1) to remove any unreacted starting 
material was followed by acidification to pH 3.0 (2M sulphuric acid) to give a solid 
which was extracted into ethyl acetate (100m1), washed with water (2 x 50m1), dried 
(MgSO4) and evaporated to give an oil which solidified on standing. 
Recrystallisation from ethyl acetate/hexane gave the title compound as a white solid 
(4g, 83 %); m.p. 134 -137 °C; (found: C,65.94;H,5.26;N,4.19, C18H17NO5 requires: 
C,66.03;H,5.24;N,4.28 %); t.l.c. (methanol/dichloromethane, 1:1) Rf 0.70; 
Dmax(nujol) 3281 (NH), 1739 (acid CO), = 1696cm 1 (urethane C =0); 
%max(Me0H) 266nm (E 24000dm3mol-lcm 1), 290nm (6100), 300nm (7500); 
8H[(CD3)2S0, 80MHz] 13.00 (1H, br s, CO2H); 8.25 (1H,d, NH); 7.95 -7.23 (8H, m, 
aromatics);5.06 (1H, d, aCH); 4.38 -4.25 (3H, m, Fmoc CH2CH); 3.24 (3H, s, ether 
OMe); 8C[(CD3)2SO, 50MHz] 169.05 (acid C =0); 156.21 (urethane C =0); 143.92, 
143.82, 140.91 (aromatic quarternary); 127.84,127.24, 125.49, 120.27 (aromatic 
CH); 80.68 (aCH); 66.13 (Fmoc CH2); 54.75 (ether OMe); 46.71 (Fmoc CH); m/z 
(FAB) 328 (MIFF), HRMS found 328.11850, C18H18NO5 requires 328.11849 
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therefore <1ppm. 
Coupling of N2- 9- Fluorenylmethoxycarbonyl-a- methoxyglycine onto 4- 
Alkoxybenzylalcohol (Wang) Resin (86) 
N,N'- Diisopropylcarbodiimide (25O111, 0.8mM) was added to a solution of Na -9- 
Fluorenylmethoxycarbonyl -a- methoxyglycine (85) (0.52g, 1.6mM) and HOBt 
(0.25g) in DMF (10m1). After sonicating for 15 minutes at room temperature this 
solution was added to a slurry of 4- alkoxybenzylalcohol functionalised resin (0.5g, 
0.8mM/g, 0.4mM), which had been pre -swollen in the minimum amount of DMF 
together with a catalytic amount of DMAP (.lmg). This mixture was then sonicated 
overnight at room temperature before being filtered, washed sequentially with DMF, 
1,4- dioxan, dichloromethane and dried to give 0.5778g of functionalised resin. The 
resin functionality was determined by UV to be 0.427mM/g (61% loading). 
Trp- Met -Asp- Phe- a- (OH)Gly (87) 
The synthesis was carried out on a 0.486mM scale using the Fmoc- a- (MeO)Gly 
functionalised 4- alkoxybenzylalcohol resin (86). All side chains were protected as 
described previously and all residues were coupled using standard double coupling 
cycles. At the completion of the assembly phase, the resin bound peptide was 
sequentially washed with DMF, 1,4- dioxan, dichloromethane and dried to give 
1.0759g of yellow solid. The peptide was then cleaved from the resin by treatment 
with TFA/water/EDT (9.5:0.5:2) for 30 minutes at room temperature. The resin was 
then removed by filtration and washed with TFA. Evaporation of the filtrate and 
trituration with diethyl ether yielded the crude peptide which was isolated by 
filtration, before being dissolved in aqueous acetic acid (20 %) and lyophilised to 
yield 80mg white solid. The peptide was purified by semi -preparative Hplc (Vydac 
C18, 250 x 22mm, 1011,M, A =H2O, B= CH3CN, 0.1% TFA; 10m1 /min. 10 -30% B 
over 28 min. 2 =214nm). The main peak eluting at 26 %B was isolated and 
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lyophilised to give 8mg (2.5 %) of the diastereomeric title compound. Analytical 
Hplc (Vydac C18, 250 x 4.6mm, 5µM, A =H2O, B= CH3CN, 0.1% TFA; lml/min. 
isocratic elution 18 %B. X=214nm) gave two peaks A and B (A Rt =16.2 min., B 
Rt =17.6 min), with the ratio of A:B = 2:1. Both these peaks were isolated seperately 
using the above analytical conditions, and were shown to be identical by mass 
spectrometry and amino acid analysis; amino acid analysis: Asp1 0.97, Met1 0.82, 
Phe1 1.03,Trp1 N /A; m/z (FAB) 671 (MH +), HRMS C31H38N6O9S requires 
670.24208, found 670.24215 therefore < 1ppm. 
Coupling of N2- 9- Fluorenylmethoxycarbonyl- a- methoxyglycine onto 2- Chlorotrityl 
chloride Resin 
A suspension of Na- 9- Fluorenylmethoxycarbonyl -a- methoxyglycine (2.1g, 6.4mM) 
in dry dichloromethane (40m1) was added to 2- chlorotritylchloride functionalised 
resin (1g, 1.6mM). Diisopropylethylamine (1.4m1) was added and the mixture was 
allowed to vortex for 20 minutes before a further aliquot of DIEA (1.4m1) was added 
and agitation continued for a further 30 minutes. The resin was then capped by 
adding methanol (2ml) and gently mixing for a further 20 minutes. The rein was then 
removed by filtration and washed sequentially with DMF, IPA, McOH and ether 
before being dried to give 1.41g of functionalised resin. The resin functionality was 
determined by UV to be 0.754mM /g (63% loading). 
Glu -Glu -Ala- Tyr- G1yTrp- Met -Asp- Phe- a- (OH)Gly (88) 
The synthesis was carried out on a 0.486mM scale using the Fmoc- a- (MeO)Gly 
functionalised 2- chlorotritylchloride resin. All side chains were protected as 
described previously and all residues were coupled using standard double coupling 
cycles. At the completion of the assembly phase, the resin bound peptide was 
sequentially washed with DMF, 1,4- dioxan, dichloromethane and dried to give 0.69g 
of solid. The peptide was then cleaved from the resin in two steps. Firstly the 
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protected peptide was cleaved from the resin by treatment with 
AcOH/TFE /dichloromethane (2:2:6, 20m1) for 60 minutes at room temperature. The 
resin was then removed by filtration and the filtrate evaporated to a small volume. 
The protected peptide was then precipitated with diethyl ether, filtered off and 
washed with water, then diethyl ether and dried to give 118mg of yellow solid. This 
yellow solid was immediately mixed with EDT (2m1) before TFA/water (9.5:5, 
10m1) was added and allowed to stir for 30 minutes at room temperature. 
Evaporation of the TFA and trituration with diethyl ether gave a pale yellow solid 
which was isolated by filtration, washed with diethyl ether and dried. Purification of 
the crude peptide by Hplc (Vydac C18, 250 x 22mm, 10µM, A =H2O, B= CH3CN, 
0.1% TFA; 10m1 /min. 10 -50% B over 28 min. X=214nm) yielded 13mg (3.75 %) of 
the pure diastereomeric title compound as a white solid after lyophilisation; Aspi 
0.97, Glx2 2.65, Glyi 1.18, Alai 0.98, Meti 0.87, Tyri 0.84, Phei 0.99,Trp1 N /A; m/z 
(FAB) 1220 (MH +), HRMS C55H69N11O19S requires 1219.44915, found 1219.44916 
therefore < + / -lppm; Hplc (Vydac C18, 250 x 22mm, 5µM, A =H2O, B= CH3CN, 
0.1% TFA; lml/min. 10 -65% B over 30 min. X=214nm) Rt = 17.8 min., 43.5 %B. 
Nuclear Magnetic Resonance Data for (88) 
The diastereomeric isomers of (88) proved inseparable by Hplc, although 2D NMR 
did allow assignment of all the signals present in the specta and indicated the 
presence of diastereomeric forms I and II in a ratio of 1:1. The full NMR assignment 
is given in table 6. 
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Residue NH a D Other 
El 3.80 1.89 yCH2 2.32 
E2 8.59 4.32 1.64,1.88 7CH2 2.30 
A3 8.12 4.25 1.15 
Y4 (I) 7.94 4.38 2.68,2.85 3,5H 6.60; 2,6H 6.99 
(II) 7.96 4.38 2.68,2.85 
G5 (I) 8.22 3.58,3.72 
(II) 8.11 3.58,3.72 
2H7.12;4H7.57; 
(I) 8.13 4.53 2.96,3.12 5H6.946H7.04; 
(II) 8.02 4.55 2.93,3.12 7H7.29;N10.74 
M7 (I) 8.25 4.28 1.79,1.84 'YCH22.36,ECH31.99 
(II) 8.15 4.30 1.75,1.83 yCH22.35,ECH31.99 
D8 8.16 4.46 2.48,2.62 
F9 (I) 8.03 4.54 2.74,3.01 2,6H 7.16; 3,5H 7.24 
4H 7.20 
(II) 7.93 4.52 2.84,3.00 
aOHG10 (I) 8.67 4.79 
(II) 8.65 4.75 
Table 6. NMR assignments for diastereomers I and II of (88) 
5H [(CD3)2S0, 600Mhz] 
Asp- Tyr- Met- Gly -Trp- Met -Asp- Phe- a- (OH)Gly (89) 
The synthesis was carried out on a 0.53mM scale using the Fmoc- a- (MeO)Gly 
functionalised 2- chlorotritylchloride resin. All side chains were protected as 
described previously and all residues were coupled using standard double coupling 
cycles. At the completion of the assembly phase, the resin bound peptide was 
sequentially washed with DMF, 1,4- dioxan, dichloromethane and dried to give 0.69g 
of solid. The peptide was then cleaved from the resin by treatment with 
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TFA/EDT /water (9:2:1, 12m1) for 60 minutes at room temperature before the resin 
was removed by filtration. Evaporation of the TFA and trituration with diethyl ether 
gave a pale yellow solid which was isolated by filtration, washed with diethyl ether 
and dried. Purification of the crude peptide by Hplc (Vydac C18, 250 x 22mm, 
10µM, A =H2O, B= CH3CN, 0.1% TFA; 9m1/min. 10 -70% B over 30 min. X= 230nm) 
yielded 36mg (6%) of the pure diastereomeric title compound as a white solid after 
lyophilisation; Aspe 1.92, Gly1 1.28, Mete 1.67, Tyr1 1.06, Phe1 1.06,Trp1 N /A; m/z 
(FAB) 1136 (Mt), HRMS C57H65N10O16S2 requires 1137.40211, found 1137.40207 
therefore < + / -lppm; Hplc (Vydac C18, 250 x 22mm, 5µM, A =H2O, B= CH3CN, 
0.1% TFA; lml/min. 10 -90% B over 30 min. ñ=214nm) Rt = 17 min., 56 %B. 
Nuclear Magnetic Resonance Data for (89) 
The diastereomeric isomers of (89) proved inseparable by Hplc, although 2D NMR 
did allow assignment of all the signals present in the specta and indicated the 
presence of diastereomeric forms I and II in a ratio of 0.8:1. The full NMR 
assignment is given in table 7. 
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Residue NH a D Other 
Dl 4.55 2.75,3.03 
Y2 8.54 4.40 2.62,2.93 3,5H 6.51; 2,6H 7.01 
M3 8.25 4.28 1.75,1.87 yCH22.40,ECH32.00 
G4 (I) 8.02 3.63,3.72 
(II) 7.97 3.65 
2H7.12;4H7.57; 
W5 (I) 8.15 4.52 2.97,3.10 5H6.946H7.04; 
(II) 8.07 4.52 2.94,3.10 
7H7.29;N10.74 
M6 (I) 8.20 4.28 1.75,1.82 7CH22.33,ECH32.00 
(II) 8.31 4.21 1.75,1.84 7CH22.33,ECH32.00 
D7 (I) 8.25 4.42 2.45,2.65 
(II) 8.15 4.50 2.45,2.65 
(I) 7.92 4.55 2.87,3.00 2,611 7.13; 3,5H 7.22 
F8 
(II) 7.87 4.32 2.80,2.98 4H 7.19 
aOHG 9 (I) 8.66 4.73 
(II) 8.70 4.76 
Table 7. NMR assignments for diastereomers I and II of (89) 
6H [(CD3)2S0, 600Mhz] 
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Angus R. Brown, Stephen L. Irving and Robert Ramage` 
Department of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3.1.1, Scotland 
Key words: affinity chromatography; Tbfmoc Na protection; porous graphitised carbon; 
tetrabenzo (a,c,g,i]fluorenyl -17- methanol; protein purification 
Abstract: The affinity of the Tbfmoc group for porous graphitised carbon has been exploited for the purification of 
synthetic peptides containing up to 85 amino acids. The hydrophobicity of the group has also been used to simplify 
peptide purification by HPLC. 
Over the last three decades great progress has been made in solid phase peptide synthesis. This, combined with the 
widespread use of HPLC for peptide purification has resulted in the synthesis of peptides containing up to 20 -30 amino acid 
residues becoming almost routine. In contrast, only a few proteins, e.g. HIV -1 protease] (99 residues) and ubiquitin2 (76 
residues), have succumbed to chemical synthesis and and crystallisation hence this area still represents a considerable challenge. 
One of the main obstacles to the stepwise chemical synthesis of proteins is the difficulty in purification of the final 
product, due to the accumulation of truncated peptides on the resin. Truncated peptides are formed when the coupling of an amino 
acid fails to go to completion and the Na- termini of these truncations are routinely capped with acetic anhydride to ensure they 
play no further part in synthesis. Several methods have been suggested for separating the desired peptide from the acetylated 
truncated peptides by derivatising the peptide N- terminus with a group capable of an affinity -type binding to a solid support. 
Examples include the binding of Na- biotinylated peptides to immobilised avidin3, Na- dinitrophenyl (DNP) peptides to 
immobilised DNP antibody4 and the reaction of an Na -thiol group with an iodoacetamide resins. 
Recently6, we reported the potential of the base labile Na- protecting group, totrabenzo[a,c,g,i)fluorenyl-17- 
methoxycarbonyl ( Tbfmoc) for affinity purification of peptides on porous graphitised carbon (PGC)7. We now report an 
improved synthesis of the Tbfmoc precursor, to trabenzo[a,c,g,i]fluorenyl -17- methanol (1) (Scheme 1), without recourse to 
chromatographic purification of intermediates, and the application of this methodology to the purification of peptides containing 
up to 85 amino acids 
Previously, the Tbfmoc group had been introduced using Tbfmoc-Gly-OH as the N- terminal amino acid in solid phase 
peptide synthesis. Although a number of Na- Tbfmoc amino acids have been prepared, it was thought to be more efficient if a 
single Tbfmoc reagent could be used to introduce the group directly onto the N- termini of resin -bound peptides. Model studies of 
the reaction of a resin -bound pentapeptide, Leu.11e.Phe.Ala.Gly- Resin, with two to trabenzo[a,c,g,i]fluorenyl -17- methyl mixed 
7129 
7130 
carbonates (2a; X= 0- nitrophenyl, 2b; X= 0- pentafluorophenyl) were carried out. The extent of reaction was monitored by HPLC 
of the crude cleaved product and showed inefficient incorporation of the Tbfmoc group. However, better results were obtained 
using chloroformate (2c; X =CI) in CH2C12 when virtually quantitative incorporation of the Tbfmoc group was observed by 
sonicating in the presence of diisopropylethylamine. A range of peptides of varying length (Table 1) were then synthesised by the 
Fmoc /t -Bu method of solid phase synthesis8. After reaction of the resin -bound peptides with chloroformate 2c, the Tbfmoc 











O- C- NH - Peptide -Resin 
2c ; X =C1 
i. Mg, Tiff; (CO2Et)2; ii. TFA/CH2C12; iii. Et3N /CH2C12; iv. Diisobutylaluminium hydride /CH2C12; v. triphosgene/ 
N,N- dimethylaniline /CH2C12; vi. Peptide- Resin /diisopropylethylamine /CH2C12 
Table 1:Peptides purified using Tbfmoc group 
Peptide No. of Amino Acids 
Table 2: Tbfmoc 3 deprotection on PGC in 70% CH3CN 
Deprotection Solution Deprotection Time 
3 Hepatitis B surface antigen 23 1% piperidine 60 min 
PreS1 (1-23) pyw10 
10% piperidine 10 min 
4 Gastrin releasing peptide 11 27 
10% triethylamine >3 h 
5 Bacteriophage X. Rai (Acm)412 66 
10% pyrrolidine 10 min 
6 MeCP2 methylated DNA 
binding domain (78- 162)13 
85 
Initial trials were carried out on peptide 3, when a solution of the crude Tbfmoc peptide in 70% aqueous acetonitrile was 
applied to a short column of PGC (50 -100 µm). HPLC of the eluent showed complete retention of the Tbfmoc peptide, whilst the 
acetylated truncated peptide impurities eluted. Deprotection of the Tbfmoc group and release of the purified peptide (Figure 1) 
was then effected by washing the column with 1% piperidine /70% aqueous acetonitrile until no further material eluted. A similar 
purification could also be achieved by simply adding PGC (either 7 µm or 50 -100 p.m) to a solution of the crude peptide in 70% 
7131 
aqueous acetonitrile, whereby the Tbfmoc peptide is adsorbed onto the surface of the PGC and the truncated impurities remained 
in solution. Adsorption of the Tbfmoc peptide onto PGC was monitored by the uy absorbance of the Tbfmoc group at 364 nm. 
The supernatant (containing the impurities) was then removed and the purified peptide released from the PGC by suitable base 
treatment. Using this procedure, the base -deprotection of the adsorbed Tbfmoc peptide was studied more closely. Several 
deprotection mixtures were tried (Table 2) and the release of the peptide from the carbon was monitored by HPLC. Surprisingly, 
deprotection of the adsorbed Tbfmoc peptide was much slower than the same reaction in homogeneous solution which is 
complete within 1 minute in 1% piperidine. This is presumably due to steric hindrance of the acidic 17 -H of the Tbfmoc group by 
the surface of the PGC. Consequently a piperidine concentration of at least 10% (v /v) is recommended for rapid deprotection of 
Tbfmoc peptides on PGC. 
Having established the criteria for efficient deprotection of the Tbfmoc group, purification of larger peptides 4 and 6 on 
PGC was attempted. In the case of peptide 4, while a reasonably good purification of the peptide was achieved (Figure 2), 
variable recoveries of product were obtained. This situation became even worse for peptide 6, when, although preferential 
adsorption of the Tbfmoc peptide 6 occurred, subsequent treatment with piperidine /aqueous acetonitrile failed to release the 
purified peptide from the PGC. These problems were traced to poor solubility of peptides 4 and 6 in piperidine /aqueous 
acetonitrile mixtures. Alternative solvent systems were tried and some success was achieved using aqueous acetonitrile solutions 
containing urea or guanidine hydrochloride. However, best results were obtained with 10 %piperidine /50% aqueous isopropanol 
which gave good recoveries of purified products. These results indicate that it is crucial to the success of this method to maintain 
conditions in which the peptide is soluble and recent experience with other synthetic proteins has shown 1:1 6M guanidine 
(a) 
\-- 
(b) (a) (b) 
If 
0 15 Ó 15 0 15 0 15 
Time (min) Time (min) Time (min) Time (min) 
Figure 1: HPLC chromatograms14 of 3: (a) crude Tbfmoc Figure 2: HPLC chromatograms15 of 4: (a) crude Tbfmoc 
peptide; (b) after purification on PGC peptide; (b) after purification on PGC 
(a) (b) (c) (a) (h) 
0 15 0 15 0 15 0 15 0 15 
Time (min) Time (min) Time (mm) Time (min) Time (min) 
Figure 3: HPLC chromatograms15 of 6: (a) crude Tbfmoc peptide; 
(b) after purification on PGC; (c) after purification by preparative 
HPLC 
Figure 4: HPLC chromatograms16 of 5: (a)crude Tbfmoc 










Scheme 2. i, glyoxylic acid; ii, McOH, sulphuric acid; iii, LiOH 
Fmoc carbamate6 4 (Scheme 2) was treated with glyoxylic acid (5 equiv.) in gently refluxing ethyl 
acetate for 6 hours to give racemic 9- fluorenylmethoxycarbonyl -a- hydroxyglycine 5 in 73% yield. The 
secondary alcohol was protected as the methyl ether 6 by 0- methylation of the a- hydroxyglycine derivatives 5 
followed by ester hydrolysis using LiOH in aqueous acetone to give 6 in 68% overall yield. Activation of 6 
(DIC/HOBT/DMAP) was used to functionalise Wang resin8 which was employed for the solid phase synthesis 
of the gastrin derivative 7 on an Applied Biosystems 430A peptide synthesiser. 
H.Trp.Met.Asp.Phe.a-OH Gly.OH 
7 
H.G1u.Glu. Ala .Tyr.Gly.Trp.Met.Asp.Phe.a -OH Gly.OH 
8 
Fmoc deprotection monitoring9 during synthesis showed low incorporation of Phe due to the instability of 
the 0- methylated a- hydroxyglycine residue10. Coupling of Asp to Phe also showed a low incorporation which 
is characteristic of diketopiperazine (DKP) formation11. This resulted in the isolation of only small amounts of 
the diastereomeric peptide 7 after cleavage (TFA/H20/EDT) and RP -HPLC. The diastereomers of 7, due to the 
R and S configuration of the terminal a- hydroxyglycine system, were separable by HPLC and were shown to 
be identical by FAB mass spectrometry and amino acid analysis. Transformation of the a -OMe substituent to 
the a -OH during acid treatment probably proceeds via the corresponding imine intermediate. 
Synthesis of the decapeptide gastrin analogue 8 was then carried out using 2- chlorotrityl chloride resin12 
in order to prevent DKP formation. Fmoc deprotection monitoring during synthesis of 8 showed no evidence of 
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Figure 2. 600Mhz 1H NMR of peptide 8 
30 
The diastereomeric decapeptides 8 were inseparable by RP -HPLC (Figure 1) but 1H NMR (600Mhz,D6 
DMSO) showed a 1:1 ratio of diastereomers with the resonances at 4.79 ppm and 4.75 ppm (Figures 2 and 3) 
assigned to the aH of an a- hydroxyglycine residue. DQF -COSY (Double Quantum Filtered Chemical Shift 
Correlation Spectroscopy) allowed a complete assignment to be made of the 1H NMR (Figure 2) and showed 
that the aH signals of the diastereoisomeric a- hydroxyglycine did not have any other crosspeaks except with 
the NH signal at 8.66 ppm and the resonance of these cars showed a downfield shift with respect to the other 
aH's. 
792 
5.4 5.2 5.0 4.8 4.6 4.4 
Figure 3. Expansion of Figure 2 to show a- hydroxyglycine aH signals 
4.2 ppm 
In conclusion,we have shown that it is possible to introduce a- methoxyglycine as the C- terminal residue 
in the' assembly phase of Fmoc solid phase peptide synthesis. Subsequent acid treatment not only causes side 
chain deprotection and cleavage of the peptide from the resin but also converts the C- terminal residue to a- 
hydroxyglycine. The biological function of the a- hydroxyglycine peptides with respect to C- terminal 
amidation is currently under investigation by Professor G.J. Dockray (Physiological Laboratory, University of 
Liverpool). 
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